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 1 
Introduction  
The objective of this thesis is to present the development of Raman spectroscopy for 
label-free biochemical identification and classification of white blood cells as a potential 
diagnostic tool for acute lymphoblastic leukemia type B (B-ALL).  
Leukemias are a diverse group of malignancies with a range of clinical presentations, 
prognoses and preferred treatment protocols. The B-ALL is a cancer of blood cells with 
the highest childhood cancer-related mortality, characterized by uncontrolled and rapid 
cell proliferation of immature B-cell progenitors that cannot mature properly into 
lymphocytic B cells [1][2]. Thus, its timely and accurate diagnosis is fundamental for 
successful clinical treatment. 
A firm diagnosis of B-ALL requires first the identification of the leukemia cells, and 
second their classification based on the differentiation/maturation stage in which the 
lymphoblastic B cells are blocked. The conventional diagnostic approach as well as the 
monitoring response to therapy is performed through a combination of morphological 
and immunophenotypic analyses of bone-marrow or peripheral-blood cells. 
Morphological approaches allow the identification of B-ALL lymphoblasts and their 
classification into three main types (L1, L2 and L3) based on cell size, 
nuclear/cytoplasmic ratio, and nucleoli evaluations. However, in some cases of poorly 
differentiated B-ALL, morphological assessment provides low sensitivity and equivocal 
results [3]. Immunophenotypic detection of specific antigens that are related to the cell 
maturation stages might have prognostic or therapeutic implications, even within a 
single acute leukemia subtype. Therefore, multiparameter flow cytometry (up to six 
colours) is used to provide detailed determination of antigen expression profiles. 
Although the immunophenotypic analysis provides relevant information, the number of 
surface proteins that can be simultaneously detected, the photobleaching of the dye 
molecules and the interference with the fluorescence of the routine stains used in the cell 
morphology assessment limit its potentiality.  
For these reasons, the development of novel diagnostic tools providing fast, highly 
sensitive and quantitative cell identification and differentiation from easily accessible 
body fluids is desirable [4].  
In the last 10 to 15 years, Raman spectroscopy (RS) have emerged as powerful optical 
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tool that utilizes molecular-specific inelastic scattering of photons to interrogate 
biological materials [5]. A Raman spectrum represents a molecular fingerprint of a cell, 
providing specific information that is related to nucleic acids, proteins, carbohydrates, 
and lipids present within the cell. The technique has a high chemical specificity and its 
attractiveness comes from its ability to provide quantitative information about cell 
morphological and physiological states in a minimally invasive or non-invasive manner 
with almost no sample preparation [6]. Different cell types in different morphological 
states will vary in their overall molecular composition and this is reflected in the Raman 
spectra, as the intensity of the Raman bands depends upon the concentration of the bio-
molecules [4-6]. Interrogation using RS minimally disturbs the native state of analysed 
cells and dynamic cellular processes at the single-cell level could be monitored, which is 
useful for assessing response to treatment.  RS has wide potential in biomedical science 
as it can be applied to samples over a wide size range from single cells to intact tissue. 
The technique is well suited for studying living cells since water solution (buffers and 
culture media) do not interfere with the experiments and there is no need for cell 
labelling (HE stain or fluorescent probes) or other cell modifications. The other major 
benefit is that resolution is limited only by the diffraction limit of the laser spot (in our 
case smaller than 0.5 µm), thus allowing high quality images of cells to be obtained. 
Additionally, RS allows probing of the sub-cellular compartments Indeed, RS has been 
used recently as a novel technique to analyze precancerous tissues in the esophagus, 
colon, and cervix [7][8][9][10], as well for the identification, classification, and 
diagnosis of many cancer types [11][12][13][14][15][16][17]. 
The aim of my PhD research project was to develop an advanced optical technique, 
based on Raman Spectroscopy (RS) and its integration with other optical (e.g. 
fluorescence microscopy, flow cytometry, Raman imaging) and biological modalities 
(e.g. Western Blotting), in order to provide a fast and reliable procedure for 
identification and classification of single cells (hemogram) from peripheral blood of 
healthy donors as well as of cancer B-ALL patients.  
The work can be divided into three main parts:  
 Deep study of Raman spectroscopy literature with particular attention to its sensitivity, 
specificity and bio-applications. 
 Development and characterization of the Raman microscope including the design of 
optics and development mathematical methods for analysis of the data (Principal 
Component Analysis). Since the aim of my thesis is to study living cells in vivo, with 
particular reference to normal and leukemia cells, the main challenges have been to 
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find correct laser wavelength and intensity, alignment and calibration of the Raman 
system and finally its application to demonstrate its usefulness.  
 Completion of four experiments that demonstrate the suitability of Raman technique 
for studies of live normal and leukemia cells. Schematically, my research project 
concerns: (i) Raman identification and classification of three leukemia cell lines, that 
closely mimic the different differentiation/maturation stages of B-ALL cells; (ii) 
Spectroscopic regression assessment of leukemia after low- and not-cytotoxic dose 
treatments of methotrexate (MTX) and 6-mercaptopurine (6MP), two key drugs 
currently used in the B-ALL maintenance therapy; (iii) RS analysis of clinical 
samples collected from peripheral blood of patients with B-ALL; (iv)  Raman 
identification and differentiation of the most important leukocyte populations isolated 
from peripheral blood of several human volunteers via conventional flow cytometry 
(granulocytes, monocytes, T cells, B cells and NK cells). 
The results presented here demonstrate that RS in conjunction with multivariate 
statistical technique has potential for rapid label-free diagnosis, classification and 
follow-up after chemotherapy treatment of B-ALL based on the optical evaluation of 
spectral features of biomolecules.   
The structure of my PhD thesis can be summarized as follow.  
In chapter 1, I show the scheme of the blood cell formations (hematopoiesis) and the 
consequences of the scheme alterations. I introduce the concept of leukemias and the 
standard methods for leukemia diagnosis. 
In chapter 2, I give an overview of the theory, show the pros and cons of the Raman 
spectroscopic technique and provide some examples of biomedical applications. 
In chapter 3, I present the experimental Raman microscope developed to analyze single 
cells and its main characteristics. I introduce the supplementary techniques used to fully 
characterize the leukemia cells: Immunofluorescence, Western blot, Raman imaging and 
Flow Cytometry. Finally, I describe the Raman spectroscopic measurements, the 
spectral processing and statistical analysis. 
In chapter 4, I describe the use of Raman spectroscopy to discriminate normal 
lymphocytic B-cells from three different B-leukemia transformed cell lines: namely 
RS4;11 and REH (both classified as L2 blast subtype) and the third cellular model 
system, MN60, is a more differentiated B-ALL cell type (classified as L3 blast subtype).  
In combination with immunofluorescence and Western blotting, I identify multiple 
intrinsic Raman peaks related to nucleic acid and protein molecular vibrations and I 
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show that these Raman markers reflect the relative changes in the potential biological 
markers from cell surface antigens, cytoplasmic proteins, and DNA content and correlate 
with the lymphoblastic B-cell maturation/differentiation stages. 
In chapter 5, I describe the use of RS to analyze the biochemical features of these B-
leukemia cell lines after low-dose and noncytotoxic treatments with methotrexate 
(MTX) and 6-mercaptopurine (6MP), the two key drugs used in current B-ALL 
maintenance therapy. To identify specific RS peaks that correlate with the different 
stages of these B-leukemia cells, I define the spectral changes after these B-ALL 
therapies in comparison with those seen under all-trans-retinoic acid (ATRA) treatment 
(used in the treatment of a different leukemia disease). Principal component analysis 
(PCA) is used to confirm the significance of these Raman spectral markers in the 
definition of the differentiation/maturation stages of B-ALL cells and in the detection of 
minimal residual disease.  
In chapter 6, I extend the RS approach to discriminate between normal B-lymphocytes 
and B-lymphocyte-enriched fractions from patients with B-ALL. At first, I analyse these 
leukemic cells using standard multi-parametric flow cytometry in order to characterize 
them based on immunophenotypic classification: Pt-1 and Pt-2 where preliminary 
classified as “common B-ALL” and Pt-3 derived from the malignant transformation of a 
B cell progenitor intermediate between the pro-B and pre-B maturation stages. I 
demonstrate that the distinctive differences in the Raman spectra between normal and 
clinical patient samples confirm and further reinforce these observations.  
In chapter 7, I show the feasibility of using RS and multivariate statistical approaches 
(PCA) to identify and discriminate leukocytes and, more in details, lymphocytes. I 
focused on five populations isolated from peripheral blood of several human volunteers 
via conventional flow cytometry: granulocytes, monocytes, T cells, B cells and NK cells. 
Finally, the thesis includes the conclusions based on the performed experiments and a 
list of the publications related to my PhD cycle. 
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    1  
Leukemia classification 
and diagnosis 
Leukemia is a group of different cancers of the blood cells that usually begin in the bone 
marrow and consist in proliferation of abnormal white blood cells. These white blood 
cells are immature cells and are called blasts or leukemia cells. 
In my research activity, I focused my attention on the most abundant white blood cells 
and, in particular, I studied one of the most common childhood leukemia: B-cell acute 
lymphoblastic leukemia (B-ALL). 
In the following chapter, I will show the scheme of the blood cell formations 
(hematopoiesis) and the consequences of the scheme alterations. I will introduce the 
concept of leukemias, the standard methods for leukemia diagnosis and show the 
advantages obtained by using the Raman Spectroscopy (RS), as novel and promising 
diagnostic technique.  
1.1 Hematopoiesis 
The hematopoiesis refers to a group of processes involved in the formation and 
maturation of the blood cells, starting from the hematopoietic stem cells (HSCs), as 
shown in Figure 1 [18]. They are found in the bone marrow and have the ability to start 
the maturation process of all the other blood cells. HSCs are self-renewing cells: during 
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proliferation, they show an asymmetric division in which some of their daughter cells 
remain as HSCs; the other daughters of HSCs (myeloid and lymphoid progenitor cells) 
cannot self-renew but they are able to start other differentiation pathways that lead to the 
production of one or more specific types of blood cells [19]. 
Therefore, HSCs give rise to both the myeloid and lymphoid lineages of blood cells. 
 
Figure 1: Diagram showing the development of different blood cells from haematopoietic stem 
cell to mature cells. 
The lymphoid lineage is composed of three types of white blood cells, also known as 
lymphocytes: T-cells, B-cells and natural killer cells (NKCs). Lymphocytes are derived 
from common lymphoid progenitors and they are the cornerstone of the adaptive 
immune system. 
The myeloid lineage is composed of megakaryocytes, granulocytes (basophil, neutrophil 
and eosinophil), erythrocytes (also called red blood cells - RBCs), monocytes and 
macrophages. They are derived from common myeloid progenitors and involved in a lot 
of different roles as innate immunity, adaptive immunity, and blood clotting. 
Many of the stages of HSCs differentiation can be purified from the bone marrow or 
peripheral blood using characteristic cell surface markers, which has greatly facilitated 
the study of hematopoietic biology and revealed important molecular alterations in 
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haematological diseases [18]. An example is the leukemia, that is a neoplastic disorder 
characterized by the proliferation of immature leucocytes (blasts) that cannot carry their 
normal functions.  
1.2 Leukemia classification 
Leukemia is a group of haematological disease consisting in the proliferation of 
abnormal/immature white blood cells. Clinically and pathologically, leukemias consist 
of several different sub-types. The first classification classes are: acute and chronic 
leukemias [20]. 
Acute leukemia is characterized by a rapid and uncontrolled proliferation of immature 
blood cells. Under these conditions, the bone marrow is unable to produce healthy blood 
cells and, due to the rapid progression and accumulation of the malignant cells, the 
leukemic cells move into the bloodstream and spread to other tissues of the body. Acute 
forms of leukemia are the most common leukemia in childhood. 
Chronic leukemia is characterized by the excessive increase of relatively mature, but 
still abnormal, white blood cells. Typically taking long time to progress, the cells are 
produced at a much higher rate than normal, resulting in many abnormal white blood 
cells. Chronic leukemia mostly occurs in older people, but can occur in any age groups. 
The leukemia diseases are further classified into lymphoblastic or myeloid leukemias, 
according to which kind of blood cell is affected.  
In the lymphoblastic leukemia, the malignant change takes place in a type of marrow 
cell that normally goes on to form lymphocytes, which are immune system cells. In 
myeloid leukemia, the malignant change takes place in a type of marrow cell that 
normally goes on to form red blood cells, some other types of white cells, and platelets. 
The leukemia classification finally includes several subtypes depending on the specific 
precursor involved. A schematic summary of the current World Health Organization 
classification for acute leukemia is presented in Table 1. 
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Table 1: World Health Organization classification for acute leukemia. 
 
In this thesis, I will concentrate my attention on acute lymphoblastic leukemia type B 
(B-ALL), that is a neoplastic disorder that shows the highest childhood cancer-related 
mortality [1]. It is characterized by immature B-cell progenitors (i.e., lymphoid or 
lymphoblastic cells) that cannot mature properly into lymphocytic B cells [1][2]. B-ALL 
is a hematological malignancy that is characterized by uncontrolled and rapid cell 
proliferation. Thus, its timely and accurate diagnosis is fundamental for successful 
clinical treatment. 
1.3  Leukemia diagnosis 
A firm diagnosis of leukemia requires a gradual approach. Firstly, the identification of 
leukemia cells from the bone marrow or peripheral blood and the distinction of leukemia 
from other neoplastic disorders; secondly, the differentiation between myeloid (ML) and 
lymphoid (LL) leukemia; finally, the classification of ML and LL into sub-categories 
that define treatment and prognostic groups. 
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In the specific case of B-ALL, the diagnosis requires first the identification of the 
leukemia cells, and second their classification based on the differentiation/maturation 
stage in which the lymphoblastic B cells are blocked. B-ALL classification is primarily 
achieved by morphological and immunophenotypic analyses of cell samples from bone 
marrow or peripheral blood [1][2][21][22][23]. 
1.3.1  Morphology and cytochemistry in the leukemia 
diagnosis 
Morphological analysis allows the identification of B-ALL lymphoblasts and their 
classification into three main types [24]:  
 The L1 type is characterized by small (10- to 15-μ) and homogenous cells, with round, 
finely reticulated to coarse chromatin, some nuclear indentation, sparse slightly 
basophilic cytoplasm, high nuclear/cytoplasmic ratio and unclear nucleoli. L1 
lymphoblasts are distinguished from normal mature lymphocytes by the homogeneity in 
their chromatin structure and their monotonous appearance. 
 The L2 type is characterized by medium-sized (14- to 18-μ) cells with more 
heterogeneity in cell size. These lymphoblasts have fine chromatin, nuclear indentation 
and tight folding in some cells, basophilic cytoplasm, lower nuclear/cytoplasmic ratio 
and visible nucleoli. L2 lymphoblasts are distinguished from myeloblasts by the 
variation in size, more basophilic cytoplasm, and lack of granules.  
 The L3 type is characterized by homogeneous, medium-sized to large cells with round, 
demarcated, and finely punctuated chromatin, no folding, deeply basophilic and 
vacuolated abundant cytoplasm, and nucleoli. Some apoptosis and fragmentation are 
usually seen. Vacuoles in the cytoplasm are not pathognomonic of Burkitt leukemia, and 
other features (eg, specific cytogenetic and immunologic characteristics) must be 
considered to make a definitive diagnosis. 
In Table 2, French-American-British (FAB) classification and description of acute 
lymphoblastic leukemia are shown.  
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Table 2: French-American-British (FAB) classification of acute lymphoblastic leukemia  
 
Figure 2 shows the images of three B-acute lymphoblastic leukemia cells according to 
the French-American-British (FAB) classification by using the May-Grünwald-Giemsa 
staining. 
 
Figure 2: Representative images of B-ALL cells using May Grünwald-Giemsa histochemical 
staining, according to FAB classification: L1 (top); L2 (middle); L3 (below). Scale bar: 10μm 
However, in some cases of poorly differentiated B-ALL, morphological assessment 
provides low sensitivity and equivocal results [3]. Although most cases can be 
diagnosed by this method, there is only a modest correlation between morphological 
categories, treatment responsiveness, and prognosis [3]. Detection of specific antigens 
that are related to these maturation stages might have prognostic or therapeutic 
implications, even within a single acute leukemia subtype.  
1.3.2  Immunophenotyping in the leukemia diagnosis 
The lineage of most cases of morphologically and cytochemically poorly differentiated 
acute leukemia can be accurately characterized by immunophenotyping. 
The morphological approach can be combined with immunophenotypic B-ALL cell 
analysis of the arrested stage of B-cell maturation in terms of the surface expression of 
up to six to eight different B-cell–associated antigens by multi-parametric flow 
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cytometry [25][26][27][28]. Using this method, the B-ALL cell lineage is currently 
defined as: 
 ‘pro–B-ALL’, when the cells originate from early pro–B lymphoblasts that express 
specific antigens (CD19 and CD38) at the plasma membrane;  
 ‘common B-ALL’, when the cells originate from late pro–B lymphoblasts or 
intermediate B-cell precursors, as identified by the expression of CD19, CD38, 
CD10, and CD79a at the plasma membrane;  
 ‘pre–B-ALL’, when the cells originate from more committed progenitors defined as 
pre–B lymphoblasts that express CD19, CD38, CD10, CD79a, CD20, CD22, and 
immunoglobulins at the plasma membrane [25]. 
However, this immunophenotypic analysis requires a panel of antibodies against several 
lymphoid-expressing antigens, and it is labor intensive and time consuming. Moreover, 
the use of fluorescent dyes is frequently limited by photobleaching of the dye molecule, 
the limited ability to detect multiple dyes, and interference with the fluorescence of the 
routine stains used in the cell morphology assessment [29]. Therefore, new approaches 
are required for rapid and sensitive diagnosis, classification, and prognosis of leukemias. 
In the next section, I will introduce the Raman spectroscopy as novel diagnostic tool to 
address those questions.  
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2 
  Raman spectroscopy 
The Raman spectroscopy is powerful tool for label-free spectroscopic and microscopic 
analysis of organic and biological materials: it allows to investigate single living cells 
in their natural environment. 
In this chapter I will give an overview of the theory, show the pros and cons of the 
spectroscopic technique and provide some examples of biomedical applications. 
2.1 Introduction to the Raman scattering 
When a laser beam interacts with a sample, it is scattered from the molecules and the 
most photons are elastically scattered (Rayleigh scattering). These scattered photons 
have the same energy (frequency) and wavelength of the incident photons. On the other 
hand, a small fraction of the light (approximately 1 in 10
6
 photons) is scattered at optical 
frequencies usually lower then the frequency of the incident photons. The process 
leading to this inelastic scatter is called Raman effect. 
In 1923 Smekal discovered the inelastic scattering theoretically [30] whereas the effect 
of the inelastic scattering of the light was first reported by the Indian physicist C. V. 
Raman and independently by G. Landsberg and L. Mandelstam, in 1928 [31][32]. By 
monitoring the scattered light from various crystalline and amorphous solids, fluids and 
gases with a mercury arc lamp, Raman succeeded to identify the inelastic scattering 
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from the additional spectral bands. He described this discovery as a "spectrum of the 
new radiation", and considered it as the result of energy exchange between the incident 
light and the scattering medium. Raman has received the Nobel Prize in 1930 for his 
work and in 1998 the Raman effect was awarded, as recognition of its significance, an 
ACS National Historical Chemical Landmark as a tool for analysing the composition of 
liquids, gases, and solids. 
The introduction and diffusion of the lasers in the 1960s allowed Raman spectroscopy to 
be more accessible to the scientific community [33][34][35]. In the 90’s, Raman 
spectroscopy was being successfully used for biochemical analysis and characterization 
after the development of sensitive detectors, optical components and the employment of 
new generation lasers [36][37][38][39][40]. 
2.2 Classical theory  
The Raman effect occurs when the incident light (monochromatic laser radiation) of γ0 
wavelength and frequency ν0 impacts upon a molecule and interacts with the electron 
cloud of that molecule. The incident photon excites one of the electrons into a virtual 
state. As for the spontaneous Raman effect, the molecule will be excited from the 
ground state to a virtual energy state, and relax into a vibrational excited state (Stokes 
Raman scattering). If the molecule is already in an elevated vibrational energy state, the 
Raman scattering is then called anti-Stokes Raman scattering (Figure 3). 
 
Figure 3: Diagram of Raman scattering by molecules. 
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The Stokes radiation occurs at lower energy (longer wavelength) than the Rayleigh 
radiation, and anti-Stokes radiation has greater energy. The energy increase or decrease 
is related to the vibrational energy levels in the ground electronic state of the molecule, 
and, the observed Raman shift of Stokes and anti-Stokes features are a direct measure of 
the vibrational energies of the molecule. 
 
Figure 4: Schematic of an induced dipole momentum by an electric field. 
A simple classical electromagnetic field description of the Raman spectroscopy can be 
used to explain many of the important features of the Raman scattering [41]. When a 
molecule is introduced into an electric field E, the latter induces an electric dipole 
momentum P in the molecule (Figure 4).  
If α is the polarizability of the molecule, then the induced dipole moment is given by: 
?⃗? 
 
=  𝛼?⃗? .         (1.1)  
When electromagnetic radiation, at frequency ν0, interacts with the molecule, this 
produces a varying electric field E whose dependence on the time t is given by:  
?⃗? 
 
= 𝐸0⃗⃗⃗⃗ 𝑐𝑜𝑠𝜔0𝑡 ,         (1.2) 
where E0 is the equilibrium value of the electric field. So, from equations 1.1 and 1.2:  
?⃗? = 𝛼𝐸0⃗⃗⃗⃗ 𝑐𝑜𝑠𝜔0𝑡 .         (1.3) 
Thus, the electromagnetic radiation induces a varying electric dipole moment, which 
then permits emission of light with the same frequency of the incident radiation. This 
phenomenon is called Rayleigh scattering. 
For non-isotropic molecules the application of an electric field in a fixed direction 
induces a moment in different direction, and α becomes a tensor. In general, molecules 
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are non-isotropic, and the three equations, which take account of the unequal 
polarizability along different principal axes of the molecule, are: 
𝑃𝑥 =  𝛼𝑥𝑥𝐸𝑥 +  𝛼𝑥𝑦𝐸𝑦 +  𝛼𝑥𝑧𝐸𝑧 ,      (1.4) 
𝑃𝑦 =  𝛼𝑦𝑥𝐸𝑥 +  𝛼𝑦𝑦𝐸𝑦 +  𝛼𝑦𝑧𝐸𝑧 ,      (1.5) 
𝑃𝑧 =  𝛼𝑧𝑥𝐸𝑥 +  𝛼𝑧𝑦𝐸𝑦 +  𝛼𝑧𝑧𝐸𝑧 ,      (1.6)  
where, for example, Px is the induced electric dipole moment in the direction of the x-
axis. The tensor α is defined by these nine coefficients αxx, αxy, αxz, … αzz. Since αxy = 
αyx, αyz = αzy, αxz = αzx the tensor α is really defined by six coefficients. If any of 
these six polarizability coefficients change during a rotation or a vibration, then the 
theory for a Raman spectrum is satisfied. For very small vibration amplitudes, the 
polarizability of the molecule is related to the normal vibrational coordinate qn by the 
equation: 
𝛼 = 𝛼0  + (
𝜕𝛼
𝜕𝑞𝑛
)0𝑞𝑛,         (1.7)  
where the label zero refers to the coordinate value at equilibrium configuration. Equation 
1.7 is the same for each of the six coefficients that define α. 
As is known, the normal coordinate qv depends on the normal vibrational frequency νv: 
𝑞𝑣  =  𝑞0𝑐𝑜𝑠(𝜔𝑛𝑡) ,         (1.8)  
where q0 is the normal coordinate of the initial position. So, substituting eq. 1.2 in eq. 
1.4, we obtain: 
𝑃𝑥 = (𝛼𝑥𝑥𝐸𝑥
0
 
+ 𝛼𝑥𝑦𝐸
 
𝑦
0 + 𝛼𝑥𝑧𝐸𝑧
0)𝑐𝑜𝑠(𝜔0𝑡) .     (1.9)  
Taking α from eq. 1.7 and qn from eq. 1.8, we have the following expression: 
𝑃𝑥 =  (𝛼
0
𝑥𝑥𝐸
 
𝑥
0
 
+ 𝛼0𝑥𝑦𝐸
 
𝑦
0 + 𝛼0𝑥𝑧𝐸𝑧
0)𝑐𝑜𝑠(𝜔0𝑡) + {(
𝜕𝛼𝑥𝑥
𝜕𝑞𝑛
)
0
𝐸𝑥
0 + (
𝜕𝛼𝑥𝑦
𝜕𝑞𝑛
)
0
𝐸𝑦
0 +
(
𝜕𝛼𝑥𝑧
𝜕𝑞𝑛
)
0
𝐸𝑧
0} 𝑞𝑛 𝑐𝑜𝑠
(𝜔𝑛𝑡)𝑐𝑜𝑠(𝜔0𝑡)            (1.10) 
Equation 1.10 may be easily converted into: 
𝑃𝑥 =  (𝛼
0
𝑥𝑥𝐸𝑥
0
 
+ 𝛼0𝑥𝑦𝐸
 
𝑦
0 + 𝛼0𝑥𝑧𝐸𝑧
0)𝑐𝑜𝑠(𝜔0𝑡) +
𝑞0
2
{(
𝜕𝛼𝑥𝑥
𝜕𝑞𝑛
)
0
𝐸𝑥
0 + (
𝜕𝛼𝑥𝑦
𝜕𝑞𝑛
)
0
𝐸𝑦
0 +
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(
𝜕𝛼𝑥𝑧
𝜕𝑞𝑛
)
0
𝐸𝑧
0} {𝑐𝑜𝑠(𝜔0 + 𝜔𝑛)𝑡 +  𝑐𝑜𝑠(𝜔0 − 𝜔𝑛)𝑡}     (1.11)  
The first term of eq. 1.11 contains only one frequency factor ω0 that is the one of the 
incident radiation. This term is interpreted in terms of the Rayleigh scattering. In 
addition to the incident frequency, the second term contains the frequencies ω0 ± ωn. 
Thus, the induced dipole moment can also oscillate with two frequencies ω0 ± ωn, 
interpreted as the vibrational frequencies. The ω0 − ωn and ω0 + ωn frequencies are 
known, respectively, as the Stokes and anti-Stokes lines.  
Equation 1.11 is important since the α0, in the first term, determines the properties of the 
Rayleigh radiation, while, in the second term, (∂α/∂qn)0 determines the properties of the 
Raman scattering. In fact, it is clear that if (∂α/∂qn)0 equals zero, so do the Stokes and 
anti-Stokes terms and there will be no Raman scattering. This gives a selection rule for 
the Raman-active motions: for a vibration to be Raman active, the polarizability of the 
molecule must change with the vibrational motion. Thus, Raman spectroscopy 
complements the IR spectroscopy (which is based on dipole moment changes). 
Although very simple classical considerations can explain the presence of the Stokes and 
anti-Stokes lines, the classical theory is the most unsatisfactory. In fact, it predicts that 
the Stokes and anti-Stokes lines should be of equal intensity, whereas in practice the 
latter are very much less intense than the former.  
For these reasons, a quantum mechanical approach is necessary to describe the intensity 
in the Stokes and anti-Stokes lines.  
2.3 Quantum theory of Raman scattering  
In the quantum theory, the Raman scattering process is considered as an excitation to a 
virtual state lower in energy than a real electronic transition with nearly coincident de-
excitation and a change in vibrational energy (Figure 5) [42]. 
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Figure 5: Representation of the quantum theory for Raman scattering. 
The expectation value of the component αij of the polarizability tensor is given by: 
⟨𝛼𝑖𝑗⟩𝑎𝑏 = ∫ 𝑢𝑏
∗(𝑞)𝛼𝑖𝑗𝑢𝑎(𝑞)𝑑𝑞 ,               (1.12)  
where the function u(q) represents the molecular eigenfunctions in the initial level a and 
the final level b. The integration extends over all nuclear coordinates. This shows that a 
computation of the intensities of Raman lines is based on the knowledge of the 
molecular wave function of the initial and final states.  
For small displacement qn the molecular potential can be approximated by a harmonic 
potential, where the coupling between the different vibrational modes can be neglected. 
The functions u(q) are then separable into a product:  
𝑢(𝑞) =  ∏ 𝜔𝑛(𝑞𝑛, 𝑣𝑛)
𝑄
𝑛=1  ,                (1.13) 
of vibrational eigenfunction of the nth normal mode with vn vibrational quanta, where Q 
= 3N-6 (or 3N-5 for linear molecules) gives the number of normal vibrational mode for 
N nuclei. Using the orthogonality relation:  
∫𝜔𝑛𝜔𝑚𝑑𝑞 =  𝛿𝑛𝑚 ,             (1.14) 
of the functions 𝜔n(qn), it follows from eq. 1.12 and eq. 1.7:  
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⟨𝛼𝑖𝑗⟩𝑎𝑏 = 𝑎𝑖𝑗
0 + ∑ (
𝜕𝛼𝑖𝑗
𝜕𝑞𝑛
)
0
∫𝜔𝑛(𝑞𝑛, 𝑣𝑎)𝑞𝑛𝜔𝑛(𝑞𝑛, 𝑣𝑏)𝑑𝑞𝑛
𝑄
𝑛=1       (1.15)  
The first term is a constant and related to the Rayleigh scattering. For non-degenerate 
vibrations the integrals in the second term becomes zero unless va = vb ± 1. In this case 
its value is [1/2(va + 1)]
1/2
 [43]. The basic intensity parameter of the vibrational Raman 
spectroscopy is the derivative (∂αij/∂q), which can be determined from the Raman 
spectra.  
The intensity of a Raman line at a Stokes or anti-Stokes frequency (ω0 ± ωn) is 
determined by the population density Ni(Ei) at the initial level Ei, by the intensity IL of 
the incident laser, and by the Raman scattering cross section σR(i → f) for the Raman 
transition Ei → Ef :   
𝐼𝑅𝑎𝑚𝑎𝑛 =  𝑁𝑖(𝐸𝑖)𝜎𝑅(𝑖 →  𝑓)𝐼𝐿 .        (1.16)  
At the thermal equilibrium, the population density Ni(Ei) follows the Boltzmann 
distribution:  
𝑁𝑖(𝐸𝑖)  =  
𝑁
𝑍
𝑔𝑖𝑒
−𝐸𝑖/𝑘𝑇         (1.17) 
with 𝑁 =
􏰄
 
∑𝑁𝑖 , the partition function 𝑍 =  ∑𝑔𝑖𝑒
−𝐸𝑖/𝑘𝑇  , and gi is the statistical 
weight. 
In the case of the Stokes radiation, the initial state of the molecules could be the 
vibrational ground state, while for the emission of anti-stokes lines the molecules should 
have initial excitation energy. Due to the lower population density in these excited levels, 
the intensity of the anti-Stokes lines is lower by a factor: 
𝐼𝑆𝑡𝑜𝑘𝑒𝑠
𝐼𝑎𝑛𝑡𝑖−𝑆𝑡𝑜𝑘𝑒𝑠
= 𝑒−(ℏ𝜔𝑛/𝑘𝑇).                   (1.18) 
The scattering cross section depends on the matrix element of the polarizability tensor 
(equation 2.15) and contains furthermore the ω4 frequency dependence. So, it can be 
written as follow [44]:  
𝜎𝑅(𝑖 → 𝑓) =  
8𝜋𝜔𝑆
4
9ℏ𝑐4
|∑
〈𝑎𝑖𝑗〉?̂?𝐿〈𝑎𝑖𝑓〉?̂?𝑆
(𝜔𝑖𝑗−𝜔𝐿−𝑖𝛾𝑗
)
+𝑗
〈𝑎𝑗𝑖〉?̂?𝐿〈𝑎𝑗𝑓〉?̂?𝑆
(𝜔𝑖𝑓−𝜔𝐿−𝑖𝛾𝑗)
|
2
,                  (1.19) 
where ?̂?𝐿 and ?̂?𝑆 are the unit vectors representing the polarization of the incident beam 
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and the scattered light. The fourth power dependence on the frequency indicates that the 
Raman intensities are 2
4
=16 times higher for green excitation at 532 nm than for red 
excitation at 1064 nm. The sum extends over all molecular levels j with homogeneous 
width γj accessible by single-photon transitions from the initial state i. It can be seen 
from eq. 1.19 that the initial and the final states are connected by two-photon transitions: 
both states have the same parity. For example, the vibrational transitions in homo-
nuclear diatomic molecules, which are forbidden for single-photon infrared transition, 
are accessible to Raman transitions.
 
2.4 Raman spectroscopy and imaging  
Raman spectroscopy does not provide direct elemental composition of the sample. The 
change in frequency of the scattered photons provides chemical and structural 
information, which is characteristic of the chemical bonds or molecules present in the 
material. By plotting the intensity of the "shifted" light versus frequency results in a 
Raman spectrum of the sample. Generally, Raman spectra are plotted with respect to the 
laser frequency such that the Rayleigh band lies at 0 cm
-1
. On this scale, the band 
positions will lie at frequencies that correspond to the energy levels of different 
functional group vibrations. The Raman spectrum can thus be interpreted similar to the 
infrared absorption spectrum and it provides information on the material chemical 
composition, state and aggregation of the sample and even in some cases details of 
factors such as stress, orientation and temperature. 
Raman scattering can be observed microscopically using typical instrumentation used 
for laser fluorescence microscopy, but instead of the fluorescence signal, the Raman 
scattering signal is detected. The incident light is focused on the biological sample by 
means of a high numerical aperture (NA) objective lens to the resolution corresponding 
to the diffraction limit. Light scattered back from the illuminated spot on the sample is 
collected by the objective, is filtered and is directed to the spectrometer.  
Raman imaging combines the spectral and spatial information. To create Raman images, 
the following steps have to be implemented:  
a) The microscope has to be coupled to the Raman spectrometer.  
b) Raman spectra of spatially resolved points have to be collected by a raster-
scanning of the focused laser beam over the sample or by moving the sample 
through the laser focus in a raster pattern via a high-resolution microscope stage. 
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The resulting data sets of several thousand individual spectra can be converted 
into spectral images. 
c) Spectral images have to be improved with different statistical methods, such as 
principal component analysis (PCA), vertex component analysis (VCA), and 
hierarchical cluster analysis (HCA) [45]. 
The total acquisition time depends on the number of spectra, the exposure time per 
spectrum, and the time for moving the stage. 
2.5 Raman advantages and disadvantages 
As a tool for characterization of chemical composition Raman spectroscopy is closely 
related to infrared (IR) spectroscopy. IR and Raman spectroscopy both measure the 
vibrational energies of molecules. In IR absorption spectroscopy the molecule absorbs 
light of a specific frequency that corresponds to the vibrational excitation. In Raman 
scattering the vibrating group in the molecule interacts with light. IR adsorption and 
Raman spectroscopy are complementary techniques (Figure 6), however they only yield 
a partial description of the internal vibrational motion of a molecule, as they are 
governed by different selection rules [46]. Raman effect is based on the inelastic 
scattering of photons by molecules and a change in the polarizability of the molecule 
occurs during the vibration. This means that the electron cloud of the molecule must 
undergo positional change. On the other hand, the infrared spectroscopy is based on 
absorption of light by vibrating molecules and the molecules undergo dipole moment 
change during vibration. So, when a molecule is symmetrical, e.g. O2, we cannot 
observe any IR absorption lines because the molecule cannot change its dipole moment. 
It has been observed that molecules with a strong dipole moment are typically hard to 
polarize, and vice versa.  
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Figure 6: Sketch of Infrared absorption and Raman scattering 
Regarding the excitation wavelength, the Raman technique uses a monochromatic beam 
or laser, in the visible, near infrared, or near ultraviolet range of the electromagnetic 
spectrum. The Raman signal intensity therefore depends inversely on the fourth power 
of the incident light wavelength, so that lasers with shorter wavelengths give a stronger 
Raman signal intensity. In IR spectroscopy, a monochromatic beam is used in the 
infrared region of the electromagnetic spectrum. The wavelength here increases or 
decreases over time, in order to observe all the absorption lines within a specific range 
of the infrared region. 
Raman scattering is a rare event, this means that it takes a long time to get a signal, 
which can also be hidden by fluorescence or other background signals. The IR 
spectroscopy, could be more sensitive than Raman, however it does not work well for 
biological samples in aqueous solutions because it suffers from large water absorption 
effects.  
Moreover, Raman does not suffer from these absorption effects and needs little or no 
sample preparation. It also has the added advantage that the concentration of the 
particular species is directly proportional to the intensity of spectral features shown. 
Infrared is only used for qualitative analysis, whereas quantitative and qualitative 
 24 
analysis is possible by Raman spectroscopy: it gives clear and accurate information and 
does not require any type of label or chemicals to be added to samples. Characteristics 
IR and Raman spectra are shown in Figure 7. 
 
Figure 7: Comparison of Infrared (black) and Raman (blue) spectra of a molecular sample 
Raman spectroscopy based techniques have many advantages, including a high chemical 
specificity and the ability to provide quantitative information about the sample in a 
minimally invasive or non-invasive manner with little or no sample preparation. The 
technique is well suited for studying live cells as water based solutions (buffer and 
culture media) do not interfere with experiments and there is no need for cell labelling or 
other cell modification as in fluorescence based approaches [47]. Raman microscopy has 
many advantages over fluorescence microscopy. First, Raman spectroscopy needs no 
external labelling and uses the induced polarizability (polarizability tensor derivative 
with respect to the normal coordinates) as a contrast in generating the vibrational spectra. 
Indeed, in a fluorescence process, the incident light should be completely absorbed by 
the sample and the system is transferred to an excited state. After a certain resonance 
lifetime it can go to different lower states. On the other hand, the Raman scattering is not 
a resonant effect and it can take place for any frequency of the incident light. In other 
words, while the fluorescence spectrum can be excited only with specific frequency of 
the incident light, whereas the Raman spectrum is independent from the excitation 
frequency. Second, biochemical signatures of the molecules are much richer as each 
component of the tissue, such as nucleic acids, lipids, biological chromophores, and 
proteins, provides its own pattern of vibrational behaviour in different spectral regions. 
Second, the new generation of Raman microscopes can offer a powerful non-destructive 
and noncontact method of sample analysis. One of the greatest benefits is the use of a 
confocal Raman microscope design. This enables a very small sample area or volume to 
be analysed down to the micrometer scale. Combining this micro Raman analysis with 
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automated focusing, XYZ movement makes possible production of “chemical” images 
of a sample with a higher spatial resolution than ever before. 
Very small amounts of material can be studied at microscopic levels in the range of 10 
microns. It can be used with solids, liquids or gasses. As mentioned above, no sample 
preparation is needed and it is a non-destructive technique. In terms of time, the spectra 
are stored relatively quickly. Further advantages include use of aqueous solutions, use of 
glass and the use of down fibre optic cables for remote sampling. On the other side, 
alloys or metallic materials cannot be used for Raman experiments. Because the Raman 
process is very weak, it leads to low sensitivity, making it difficult to measure low 
concentrations of a substance; for this reason the detection needs a sensitive and highly 
optimized instrumentation. Moreover, the intense laser radiation can destroy the sample 
and large background signals from fluorescence of impurities or of the sample can hide 
the Raman spectrum [46]. 
2.6 Applications in Biomedicine 
The application of Raman spectroscopy to biological molecules has rapidly grown up 
since the early 1970s, presumably because of the development of lasers (monochromatic 
and coherent sources of light) and modern dispersive spectrometers. At first, the Raman 
application was completely focused on the collection of a spectral database recorded 
from different important biological molecules (proteins, nucleic acids, phospholipids 
and so on) in aqueous solutions, i.e. natural medium of biological molecules and systems. 
Later, Raman Spectroscopy has proved to be a promising and powerful technique to 
study more complex systems such as living cells and tissues [48]. The potential of 
conventional Raman spectroscopy as an interrogation method of cell structure and status 
is based on the fact that the Raman spectrum of a cell represents an information rich 
“fingerprint” of the overall biochemical composition of the cell. The information 
obtained is related to the intrinsic molecular composition of the cell, thus no labels or 
other contrast enhancing chemicals need to be used. The detection of time-dependent 
biochemical changes of cells has the potential to provide the additional level of 
information needed for quantification and discrimination of a wider range of toxic 
agents.  
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Figure 8: Typical Raman spectrum of a cell and of main biopolymers found in cells. 
Table 3: Peak assignment for Raman spectra of living cell. 
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Raman spectra of live cells consist of bands corresponding to all biopolymers found in 
cells (Figure 8). The peak assignment of these spectra is presented in Table 3 [49]. 
Nucleic acids can be identified by peaks characteristic of nucleotide and sugar-
phosphate backbone vibrations. The main peaks are found at 1095 cm
-1
 (phosphodioxy 
group PO2-), 788 cm
-1
 (C5-O-P-O-C3 phosphodiester bonds in DNA) and 813 cm
-1
 (C5’ 
-O-P-O-C3’ phosphodiester bonds in RNA), 782 cm-1 (thymine, cytosine and uracil) and 
1578 cm
-1
 (guanine and adenine). The phosphate peaks are particularly useful to 
determine the structure of DNA (A, B or Z forms) and also provide the main distinction 
between DNA and RNA. The spectra of proteins are dominated by peaks corresponding 
to the Amide I (1660-1670 cm
-1
) and Amide III (1200-1300 cm
-1
) vibrations, which have 
been shown to be sensitive to the secondary structure of the proteins. There are 
additional Raman peaks corresponding mainly to amino acids containing phenyl groups, 
such as phenylalanine (1005 cm
-1
), tyrosine (854 cm
-1
) and tryptophan (760 cm
-1
) as 
well as C-H vibrations (1449 cm
-1
). While it is difficult to distinguish between specific 
types of proteins on the basis of their Raman spectra, the Amide I and Amide III peaks 
are sensitive to subtle changes in the secondary structure of proteins. The strongest 
Raman peaks of lipids are present at 1449 cm
-1
, 1301 cm
-1
 (C-H vibrations) and 1660 
cm
-1
 (C=C stretching) and belong to vibrations of the hydrocarbon chains. Additional 
Raman peaks corresponding to head groups of phospholipids can also be found, such as 
the 719 cm
-1
 peak corresponding to the C-C-N+ symmetric stretching in 
phosphatidylcholine, a major constituent of cellular membranes. Carbohydrates can be 
identified and analysed reliably due to their characteristic Raman peaks of sugars, 
especially the C-O-C vibrations of the glycosidic bonds and sugar rings (800-1100 cm
-
1
).  
Cells of different type or in different physiological states will show a different molecular 
composition. Raman spectra reveal the overall molecular composition, and so spectra 
will be different depending on the concentration of the molecules. Pathological changes 
in molecular composition or structure are shown by the spectra, allowing development 
of diagnostic tools based on Raman spectroscopy [50][51][52]. 
Although interesting spectral information has been obtained from suspensions of cells 
[53], single cell spectra offer important information concerning specific biological 
functions, cellular interactions with other cells, drugs, biomaterials and so on. Raman 
spectroscopy has been used to examine single fixed [54][55], dried [56], and living cells 
[57][58][59] grown or deposited on specific "Raman-transparent" substrates (usually 
quartz or CaF2 slides). Recent reports showed the capability of Raman microscopy to 
study nucleic acids in cells under different conditions [53], to detect molecular changes 
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during cell death [60][61][62][63], to study the interaction of cells with toxic agents [64], 
to identify differences between active and non-active T-lymphocytes [65]. Since Raman 
spectroscopy methods have been used for many years, there are a a lot of recent 
excellent reviews of Raman spectroscopy as a tool for life science and biomedical 
research [49][66][67][68][69][70][71][72]. 
Raman spectroscopy was recently applied to achieve an early detection of cancers, to 
control the effect of various agents on the tissue, to identify and differentiate several 
pathogenic microorganisms found in blood infections [73]. Raman spectroscopy can 
also discriminate healthy tissue from diseased tissue, due to the chemical changes 
resulting from a disease. For instance Huang et al. used near infrared Raman 
spectroscopy to distinguish healthy bronchial tissue from tumor tissue [74]. Haka et al. 
demonstrated the potential of Raman spectroscopy to diagnose breast cancer lesions [75]. 
Furthermore, the progress in microcomputer manufacturing together with the elaboration 
of rapid mathematical and statistical algorithms, offer to Raman spectroscopy the 
possibility of acting as a powerful imaging tool. A Raman image, collected from a 
complex biological system, i.e. cell or tissue, can provide useful information on the 
localization or distribution of different constituting molecules [76].  
Optical Raman imaging has emerged from the Raman spectroscopy technique as a new 
method which allows real time, non-invasive, high-resolution imaging of tissue, with a 
particular focus on cancer diagnosis. Recently, more sensitive detectors have become 
available, making the technique easily applicable [77]. 
Lately, Raman spectroscopy has been applied to investigate the differences between the 
leukocyte subtypes which have been obtained from healthy donors. Raman imaging was 
able to display the same morphological features as standard staining methods without 
using any labels and to separate Raman spectra of the two most abundant leukocytes, the 
neutrophils and lymphocytes (CD4
+
 T-lymphocytes) [78].  
It was also natural to use Raman spectroscopy as a tool for diagnosis, for instance in 
analyzing metabolic effects in biological fluids, or alterations induced in tissues upon 
cancer formation, such as changes in DNA, protein and lipid conformations, or 
molecular degradation. Thanks to the continuing technical progress, Raman 
spectrometers can be used in the future as a non-invasive tool for biomedical diagnosis.  
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   3 
Experimental methods and 
data analysis 
In this chapter, I will present the experimental Raman microscope developed to analyze 
single cells and its main characteristics. I will introduce the supplementary techniques 
used to fully characterize the leukemia cells: Immunofluorescence and Western blot 
analysis. Finally, I will describe the Raman spectroscopic measurements, the spectral 
processing and statistical analysis. 
3.1 Raman experimental setup  
A sketch of the Raman setup, built up in the Biophotonics laboratory of Dr. A. C. De 
Luca, is shown in Figure 9 [79][80]. It consists of three major components:  
1. Excitation source (laser).  
2. Microscope and light collection optics (microscope, mirrors, filters and lenses).  
3. Detection optics (Spectrometer and CCD). 
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Figure 9: Schematic of our Raman microscope system (M-mirror; L-lens; F-filter; BS-beam 
splitter; NF-notch filter; BPF-band pass filter). 
3.1.1 Laser  
Cell biomolecules are sensitive to light and this makes the choice of laser parameters 
crucial for studying living cell. Three effects in particular need to be considered: cell 
photo-damage, which is a light-induced reduction in cell viability, excitation of sample/ 
medium autofluorescence and efficiency of the Raman scattering. 
Considering these features, the Raman probe used was a green diode laser (Opus, Laser 
Quantum) at 532 nm. It provides a maximum power of 2 W and exhibits excellent beam 
parameters and power stability.  
The average laser excitation power on the sample was 2 mW, to avoid cellular damage 
and degradation. Raman spectra were recorded using an integration time of 20 s. 
The laser output characteristics are reported in the Table 4. 
 
 
 32 
   Table 4: Opus 532 laser output specification 
Power 2 W 
Wavelength 532nm 
Beam Diameter 1.85mm ± 0.2mm 
Spatial Mode TEM00 
Bandwidth 45 +/- 10GHz 
Divergence <0.44 +/- 0.07mrad 
Power Stability <0.2% RMS 
Noise <0.08% RMS 
Noise Bandwidth 10Hz - 100MHz 
Pointing Stability <2μrad/°C 
Polarisation Ratio >100:1 
Polarisation Direction Horizontal 
Coherence Length 0.7cm 
Beam Angle <1mrad 
Operating Temp 15 - 40ºC 
Umbilical Length 1.5m 
 
3.1.2 Microscope and light collection optics  
The laser beam at 532 nm was spatially filtered using a laser-transmitting filter (Maxline, 
Semrock) and expanded by a telescopic system. The telescopic system, formed by lenses 
L1 (f1 = 50 mm) and L2 (f2 = 150 mm), gives a linear magnification of M = f2/f1 = 3. As 
matter of fact, the laser beam diameter at the end of the telescope was around 6 mm. The 
laser beam was introduced in an inverted microscope (Olympus IX51) to illuminate the 
sample. The use of the inverted Raman micro-spectrometer offers more flexibility for 
performing Raman spectral imaging and time-course experiments on live cells, since 
cells are not disturbed during experiments. The most important component of the 
microscope in Raman microscopy is the objective: 60x objective lens (Olympus 
UPLSAPO 60XW, water immersion, numerical aperture 1.2). It focuses the laser beam 
onto the sample as well as collects the resultant Raman scattered light from the sample. 
For Raman spectral imaging of cells, the following characteristic of the objective was 
considered: i) high numerical aperture (NA) allowing high resolution and collection of 
light, ii) low background.  
The back-scattered light from the sample was collected from the same objective and 
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filtered from a dichroic beam-splitter (RazorEdge 45° beam-splitter, Semrock), where 
the radiation at 532 nm was cut. The Raman light was filtered using a laser-blocking 
filter (RazorEdge 0° notch filter, Semrock) to eliminate the residual Rayleigh scattering 
and then focused onto the entrance slit of the monochromator (Acton SP2300, Princeton 
Instruments). The Raman scattered light was finally detected by using a back-
illuminated CCD. The detector was interfaced to a personal computer, where spectra 
were stored and analysed. 
Halogen lamps light, focused on the sample by a condenser (working distance = 27 mm 
and NA = 0,55), and a digital camera (Olympus Soft Imaging LC20), coupled to 
microscope, were used to image the sample on a display during the acquisition.  
The sample chamber is made up by a 150 μm quartz coverslip (UQG Optics), a 100 μm 
spacer and a 1 mm quartz microscope slide; the chamber is sealed and mounted on the 
manual X-Y microscope stage.  
3.1.3 The detection optics  
The Raman radiation, coming from the sample, has been detected by using a 
monochromator (ACTON SP2300, Princeton Instruments) set at 250 μm to reject the 
off-focus light in order to increase the signal-to-noise (SNR) ratio and a back-
illuminated charge-coupled device (PIXIS:400BR-eXcelon CCD, 1340x400 pixels, 
Princeton Instruments), and placed at the monochromator exit. 
The spectrometer, consisting of two concave mirrors and one plano diffraction grating 
(f/3.9 Czerny-Turner configuration, Figure 10), separates the incident light into its 
component wavelengths so the relative amounts of radiation at each wavelength can be 
measured. A lens (f = 50 mm) is placed in front of the spectrometer to ensure the best 
focusing of the Raman photons onto the spectrograph slit. Focused light enters the 
spectrograph through an entrance slit (250 µm) and is then collimated and shone on a 
grating (1200 grooves/mm reflective diffraction grating, 750 nm blaze wavelength), 
which disperses the light providing an estimated spectral resolution of approximately 1 
cm
−1
. 
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  Figure 10: Schematic of spectrometer (Czerny-Turner configuration). 
In Figure 11 the efficiency curve of the diffraction grating of the monochromator is 
shown. 
 
Figure 11: Efficiency curve of 1200 lines/mm reflective diffraction grating (at 750 nm blaze 
wavelength). 
Finally, the dispersed light is collected from the CCD camera. The CCD used in our 
system is a back-illuminated CCD (PIXIS:400BR-eXcelon) thermoelectrically cooled at 
70ºC. Thanks to the cooling technology, PIXIS camera offers extremely low dark 
current, which is a slow and steady growth of unwanted signal generated by the heat 
inside the detector. The advantage of back illuminated chips is that the surface is clear of 
obstruction (the back of the CCD has no electrodes), therefore is more sensitive. 
Moreover, the PIXIS eXcelon
TM
 technology increases the CCD sensitivity while 
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suppressing etalon interference fringes observed in the NIR with conventional back-
illuminated devices (Figure 12). 
 
Figure 12: Comparison of etaloning performance of eXcelon vs. back-illuminated CCDs. 
Figure 13 shows the quantum efficiency of PIXIS CCD with eXcelon
TM
 technology. 
 
Figure 13: Quantum efficiency of PIXIS back-illuminated CCD. 
3.2 Sample preparation  
B-ALL cell lines. We used B-Acute Lymphoblastic Leukemia cells (B-ALL) as 
biological model in the Raman experiments: the RS4;11, REH and MN60 B-leukemia 
cell lines were obtained from Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (Germany) (Figure 14). The RS4;11 cell line (an L2 
subtype) was originally derived from a 32-year-old female patient with B-ALL at 
relapse [81][82]. The REH B-leukemia cell line was originally derived from a 15-year-
old male patient with common B-ALL at relapse, and these are morphologically similar 
to the RS4;11 B-leukemia cells [83]. The MN60 B-leukemia cell line (an L3 subtype) 
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was originally derived from a 20-year-old male patient with B-ALL during remission 
phase [82]. The RS4;11 and MN60 B-leukemia cell lines [81] were maintained in α-
MEM supplemented with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 50 U/mL 
penicillin and 50 μg/mL streptomycin. The REH B-leukemia cell line [36] was 
maintained in RPMI supplemented with 20% (v/v) fetal bovine serum, 2 mM L-
glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin. For the drug treatments, a 10 
mM stock solution of 6MP in 1 M NaOH and 10 mM stock solutions of MTX and 
ATRA in dimethylsulfoxide were diluted in cell cultured medium, and the cells were 
treated for 72h before processing for Immunofluorescence or Western blotting. It is 
important to note that the final concentration of dimethylsulfoxide in these treatments 
was at least 100-fold below the described differentiating concentration for 
dimethylsulfoxide [85]. 
 
Figure 14: Experimental model of B-ALL differentiation. 
B- and B-ALL cells. B lymphocyte populations were collected from peripheral blood of 
healthy volunteers or leukemia patients. Normal B-cell-enriched fraction of lymphocytes 
was obtained using EasySep Negative selection kits (Stemcell Technologies Inc) for 
heparinized venous blood obtained from healthy volunteers [86], and according to the 
manufacturer instructions. B-ALL cells were collected from the peripheral blood of 
three male patients with B-ALL (Age 22-, 5 and 23-years old for Pt-1, Pt2 and Pt3, 
respectively). Blood samples for all patients were withdrawn at diagnosis, prior to 
therapeutic regimen start. After the samples were collected, mononuclear cells were 
purified using Ficoll-Histopaque 1.077 g/mL density gradient centrifugation (Figure 15). 
As the B-ALL cells were then around 95% of the purified fraction, no further step was 
used for these B-ALL cells. Before the RS, the cells were treated with 10 mg/mL 
DNAse-I solution (Stemcell Technologies Inc) to digest the DNA from damaged cells. 
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This step was important to reduce viscosity, and to remove membrane-bound DNA 
fragments that could interfere with the RS analysis. Informed consent for the use of 
biological samples for research purposes was obtained from both the healthy volunteers 
and the patients with B-ALL. The lymphocytes in the B-enriched fractions were 
routinely >98% surface immunoglobulin positive, as assessed by flow cytometry. 
 
Figure 15: Ficoll-Histopaque procedure for isolation of lymphocytes (B-cells). 
Leucocytes. An established protocol for leukocyte separation from peripheral blood of 
healthy donors based on Ficoll-Histopaque 1.077 g/mL density gradient centrifugation 
has been used. After the centrifugation, the granulocytes precipitate to the bottom of the 
Ficoll tube together with the majority of the red cells (Figure 15). The lymphocytes and 
monocytes remain in the middle of the tube (buffy coat). The monocyte and lymphocyte 
populations were separated by collecting the buffy coat and using a specific 
immunomagnetic separation procedure (EasySep Negative selection kit, Stemcell 
Technologies Inc) for monocytes, B cells, T cells and NK-cells, respectively, and 
according to the manufacturer instructions [86].  Instead, the granulocytes were obtained 
simply collecting the red pellet at the bottom of Ficoll tubes and lysing the red cells with 
ammonium chloride. 
3.3 Raman wavelength calibration 
The Raman spectrum of the polystyrene bead (5 μm-sized) was acquired for the 
wavelength calibration of the system. The standard software interface WinSpec is used 
to control and acquire data from CCD camera. After data acquisition (acquisition time 
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2s), the collected data are saved as ASCII files and analysed by using the Origin 9.0 
software.  
The Raman spectrum of the polystyrene bead was used to precisely set a wavenumber 
for each individual detector pixel. Indeed, the polystyrene Raman spectrum is well 
known: there is a collection of over 1000 Raman spectra of a wide range of compounds 
compiled by Professor Richard L. McCreery’s research group, including polystyrene 
(Figure 16) [87]. 
 
 Figure 16: Raman spectrum of polystyrene from McCreery group. 
As shown in Figure 17a, a straight line fits the calibration points distributed over the 
whole spectral region of interest. In this way, the pixels were associated to the 
appropriate relative cm
-1
 values. The final spectral resolution was 1 cm
-1
. In Figure 17b 
we reported the acquired Raman spectrum of a polystyrene bead that was used for 
wavelength calibration of the system.  
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Figure 17: (a) Raman peaks position in pixel as a function of the wavenumber values. A linear 
fit of the experimental data is also shown. (b) Calibrated Raman spectrum of a polystyrene bead. 
The acquisition time is 2 s. Laser power on the sample is 2 mW. 
3.4 Raman system spatial resolution  
We experimentally measured the resolution of our system by acquiring the Raman signal 
of a 0.5 μm polystyrene bead and scanning the laser probe in the x (step size 20 nm) and 
z (step size 50 nm) directions, as shown in the figure below. We measured the FWHM 
from a Gaussian fit of the experimental data and the achieved resolution was σx = σy = 
0.9 μm and σz = 4.0 μm (along optical axis) (Figure 18). The axial resolution (σz) was 
further checked by measuring the variation of the Raman signal acquired from the center 
of polystyrene bead as a function of the bead size (Figure 19).  
 
Figure 18: (a) Resolution and FWHM value along X-axis. (b) Resolution and FWHM value 
along Z-axis. 
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By moving from 4 μm to 5 μm -sized polystyrene bead the signal does not increase 
linearly, confirming that the axial resolution of the Raman microscope was about 4 μm. 
The probe volume, approximately calculated as the volume of a cylinder with a base 
diameter of 0.9 μm and a height of 4.0 μm, was about 2.54 μm3.  
Therefore, even if the laser position, during acquisition, was focused on the cell nucleus, 
we can conclude that a large volume of the cell is investigated including the cytoplasm 
and cell membrane. 
 
Figure 19: Raman signal from the center of polystyrene bead as a function of the bead size. 
3.5 Raman measurements and spectral processing 
All of the spectral signals were acquired taking into account four key experimental 
parameters.  
i. During acquisition, the laser was focused on the lymphocyte nucleus to limit the 
spectral variability from individual cells.  
ii. For each cell type, the cells analyzed were derived from different cultures, to 
ensure that the observed differences were the result of biological variations rather 
than variations in instrument background or cell culture conditions. 
iii. For each experimental session, more than 50 cells were analyzed, to take into 
account possible biochemical differences in the spectral data due to variations in 
cell-cycle progression.  
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iv. The spectra that were obtained from cells with morphological alterations due to 
apoptotic status or that were in transition through the mitosis phase (visible and 
well defined under optical microscopy) were not included in the subsequent 
analyses.  
The average laser excitation power on the sample was 2 mW, to avoid cellular damage 
and degradation. Raman spectra in the range between 600–1800 cm−1 were recorded 
using an integration time of 20 s and a spectral resolution of 1 cm
−1
. To be suitable for 
Raman analysis, the cells were transferred to a quartz slide and the spectra measured 
within 1 h of the removal of the culture medium. A Matlab script was used to align the 
spectra to compensate for any small drift in the laser wavelength over the experimental 
period. All the spectra were corrected for the quartz coverslip and PBS solution Raman 
spectrum, by subtracting the background spectrum. The Raman spectra were background 
corrected by subtracting a third-order polynomial fit. The data were finally normalized 
with respect to the highest peak (Raman band at 1659 cm
−1
).  
3.6 Statistical analysis 
Principal Component Analysis 
For data analysis, a program developed in the Matlab platform based on Principal 
Component Analysis (PCA) was used. PCA is a multivariate technique that operates in 
an unsupervised manner and is used to analyse the inherent structure of the data [88].  
Principal component analysis (PCA) is a statistical procedure that uses an orthogonal 
transformation to convert a set of correlated variables into a set of linearly uncorrelated 
variables called principal components (PCs). I will show below a detailed description of 
PCA using the covariance method. 
The aim is to transform a given data set X of dimension p to an alternative data set Y of 
smaller dimension L << p.  
The data are arranged as a set of n data vectors x1 … xn and each xi has p columns. We 
place the row vectors into a single matrix X of dimensions n × p. 
After that, we have to calculate the empirical mean along each dimension j = 1,…, p and 
place the calculated mean values into an empirical mean vector u of dimensions p × 1. 
𝑢 [𝑗] =
1
𝑛
∑𝑋[𝑖, 𝑗]
𝑛
𝑖=1
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Mean subtraction is an integral part of the solution towards finding a principal 
component basis that minimizes the mean square error of approximating the data.
 
Therefore, we have to centre the data subtracting the empirical mean vector u from each 
row of the data matrix X. Then, we place mean-subtracted data in the n × p matrix B. 
𝐵 = 𝑋 − ℎ𝑢𝑇 
where h is an n × 1 column vector of all 1s: 
ℎ[𝑖] = 1             for 𝑖 = 1, … , 𝑛 
At this point, we calculate the p × p empirical covariance matrix C from the outer 
product of matrix B with itself: 
𝐶 =
1
𝑛 − 1
𝐵∗ ∙ 𝐵 
where the * is the conjugate transpose operator. If B consists of real numbers, the 
"conjugate transpose" is the same as the regular transpose. 
To calculate the matrix V of eigenvectors which diagonalizes the covariance matrix C, 
we use the following formula: 
𝑉−1𝐶𝑉 = 𝐷 
where D is the diagonal matrix of eigenvalues of C. Matrix D will have the form of 
an p × p diagonal matrix, where 
𝐷[𝑘, 𝑙] = 𝜆𝑘        for 𝑘 = 𝑙 
is the j-th eigenvalue of the covariance matrix C, and 
𝐷[𝑘, 𝑙] = 0         for 𝑘 ≠ 𝑙 
Moreover, the matrix V, which has dimension p × p, contains p column vectors, each of 
length p, which represent the p eigenvectors of the covariance matrix C. 
Now, we have to select a subset of the eigenvectors as basis vectors. So, we take the 
first L columns of V and create a new p × L matrix W: 
𝑊[𝑘, 𝑙] = 𝑉[𝑘, 𝑙]     for        𝑘 = 1,… , 𝑝          𝑙 = 1,… , 𝐿 
where 1 ≤ 𝐿 ≤ 𝑝. 
The Principal Components (PCs) correspond to linear combinations of the original 
variables, which are orthogonal to each other and designed in such a way that each one 
successively accounts for the maximum variability of the dataset. The final step is to 
project the original data onto new eigenspace and when the PC scores are plotted they 
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can reveal relationships between samples (groupings). 
Leave-one-out cross validation 
The leave-one-out method was used for cross validation of the model. In this method, 
we performed PCA of the whole dataset without one spectrum. The resultant model was 
used to predict the classification of the left-out sample spectrum. This cross validation 
approach was used for each spectrum in the set, and we constructed a confusion matrix 
that summarizes the correct and incorrect spectra classifications [89]. Each row of the 
confusion matrix gives the predicted classification for a specific cell type. The diagonal 
terms of the confusion matrix give the number of correct predictive classifications, and 
by taking into account the mean of these values, it is possible to obtain information on 
the efficiency of the method. 
Empirical approach 
Non-parametric diagnostic algorithms based on peak intensities, spectral bandwidths, 
and/or peak ratios have been widely employed in literature to correlate the variations of 
cell spectra with cancer cells in a simple and straightforward fashion [36][74][90]. In 
this thesis, the empirical diagnostic algorithm based on the ratio of the Raman peak 
intensity at 1447 cm
-1
 for CH2 proteins/lipids to the peak intensity at 785 cm
-1
 for DNA 
was selected for cell classification. The unpaired Student's t-test was used to test the 
difference of Raman intensity ratio (I1447/I785) between normal and leukemia cells.  
3.7 Confocal Raman imaging (Xplora Horiba)  
The inverted confocal Xplora microscope (Horiba, Jobin Yvonne) has been used for 
micro-Raman imaging experiments. The inverted confocal microscope is coupled to a 
full Raman module mounted above which includes: three laser sources, a 200 mm focal 
length spectrograph and a CCD camera. 
The different excitation wavelengths are supplied by three internal lasers: 
 A 532 nm solid state laser, maximum power 25 mW; 
 A 638 nm diode laser, maximum power 30 mW; 
 A 785 nm diode laser, maximum power 100 mW. 
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Figure 20: XploRA inverted Raman microscope. 
 
The optical path is split into two parts: the illumination (laser) path and the collection 
(Raman signal) path (Figure 20). On the incoming laser path, the laser beam is reflected 
toward the microscope (Nikon, Ti-2000 Eclipse Series, including three objectives: 10x, 
NA = 0.3; 60x water immersion, NA = 1.2; 100x oil immersion, NA = 1.25) by the use 
of a special filter (dielectric edge rejection filter). It is used in injection/rejection mode 
which firstly directs the laser into the microscope and then filters out the Rayleigh 
scattered light as it returns to the spectrograph allowing only the Raman scattered light 
alone to be transmitted through to the confocal hole (motorized confocal pinhole with 
four allowed positions: 100, 300, 500 nm) and the entrance of the spectrograph (entrance 
slit positions: 50, 100, 200 µm). The integrated spectrometer is an asymmetric Czerny 
Turner design (F = 200 mm), which is optimized for a flat field output and with minimal 
optical aberrations. The following gratings are mounted on four position kinematic 
interchangeable grating turret: 600 gr/mm, 1200 gr/mm, 1800 gr/mm and 2400 gr/mm. 
This set of 4 gratings is used to cover the full spectral resolution and range of the 
instrument when configured with three lasers. In Table 5, dispersion, resolution and cut-
off characteristics of the system are summarized.  
A motorized XY stage (Stage travel 100mm x 120mm, steps= 100 nm) is used to move 
the sample under microscope.  
The camera is an open-electrode CCD (Andor, iDus DU420A-OE325, 1024x255 pixels) 
cooled at –80°C. In Figure 21 the CCD quantum efficiency is reported.  
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Table 5: Scheme of the dispersion, resolution and cut-off characteristics of the Xplora system. 
 
 
Figure 21: Quantum efficiency of Andor OE-CCD camera (yellow curve). 
3.8 Immunofluorescence microscopy 
Immunofluorescence (IF) microscopy is a relevant technique generally used to assess 
both the localization and expression levels of proteins of interest in cells. This technique 
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uses the antibodies to label a specific target antigen with a fluorescent dye (fluorophors 
or fluorochrome), and therefore allows to display the distribution of the target molecule 
through the sample by using a fluorescence microscope. Immunofluorescence can be 
used on tissue sections, cultured cell lines, or individual cells, and may be used to 
analyse the distribution of proteins and small biological and non-biological molecules. 
Moreover, it can be used in combination with non-antibody methods of fluorescent 
staining, for example, DAPI or Hoechst to label DNA. Several microscope designs can 
be used for analysis of immunofluorescence samples: epifluorescence and confocal 
microscope are the most widely used. 
There are two categories of immunofluorescence techniques, primary (or direct) and 
secondary (or indirect). Primary immunofluorescence uses a single, primary antibody, 
chemically linked to a fluorophore. The primary antibody recognizes the target molecule 
(antigen) and binds to a specific region. After a laser light excites the attached 
fluorophore, it will emit a specific wavelength and can be detected by fluorescence 
microscopy. Secondary immunofluorescence uses two antibodies; the unlabelled first 
(primary) antibody specifically binds the target molecule, and the secondary antibody, 
which binds the fluorophore, recognizes the primary antibody and binds to it. This 
protocol is more complex and time consuming than the primary protocol but allows 
more flexibility because a variety of different secondary antibodies can be used to bind a 
specific primary antibody [91].  
In the following paragraphs, I will describe the secondary immunofluorescence 
protocols used for the leukemia cell preparations and some details concerning the 
confocal imaging analysis.  
3.8.1 Sample preparation 
The three B-ALL cell lines, RS4;11 (6 ×10
4
), REH (1 ×10
5
), and MN60 (3 ×10
4
), were 
suspended in 1 mL culture medium, plated onto 15-mm coverslips in a 24-well plates for 
24 h, and then fixed with 2% paraformaldehyde (supplemented with 2 µg/mL Hoechst 
33342, as the DNA dye) overnight at 4 °C. The cells were washed three times with 
phosphate-buffered saline (PBS), incubated in blocking solution (0.5% BSA, 0.05% 
saponin, 50 mM NH4Cl, in PBS, pH 7.4) for 20 min at room temperature, and then 
incubated with the specified antibodies (CD38 1:50; CD20, CD19 1:10) diluted in 
blocking solution, overnight at 4 °C. After three washes with PBS, the cells were 
incubated with an Alexa 546-conjugated anti-mouse goat antibody (1:400 diluted in 
blocking solution) for 45 min at room temperature, and then washed again three times 
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with PBS and twice with sterile water, to remove salt. The coverslips were mounted on 
glass microscope slides with Mowiol. 
3.8.2 Immunofluorescence confocal imaging  
 
  Figure 22: Confocal Zeiss inverted LSM700 microscope 
Confocal images were acquired and analyzed using an inverted confocal microscope 
system (Zeiss LSM700; Carl Zeiss) with a 63x oil-immersion objective with a resolution 
of 1024 × 1024 pixels, with the files exported as Tiff files (Figure 22). The images were 
cropped and optimized for brightness and contrast with Photoshop, and composed using 
Illustrator (Adobe Systems). 
3.9  Western blotting 
Western blotting is a widely used analytical technique detecting specific proteins in a 
tissue homogenate or cellular extract. In this technique a mixture of proteins is separated 
depending on molecular weight, and thus by type, through gel electrophoresis. The 
proteins are then transferred to a membrane (typically nitrocellulose or PVDF), 
producing a band for each of them. The membrane is then incubated with labels 
antibodies specific to the protein of interest. The unbound antibody is washed off while 
the bound antibodies are then detected by developing the film. As the antibodies only 
bind to the protein of interest, only one band should be visible. The thickness of the band 
corresponds to the amount of protein present [92]. 
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In the following paragraph, I will present the Western blotting protocol used for the 
leukemia cell preparations. 
3.9.1 Sample preparation 
RS4;11 (6 ×104), REH (1 x105), and MN60 (3 ×104) cells were suspended in 2 mL 
cultured medium in 6-well plates for 72 h and then lysed with 100 µL Laemmli buffer. 
The total proteins were separated on 10% SDS-PAGE, transferred onto nitrocellulose, 
and subjected to Western blotting. The nitrocellulose filters containing the proteins of 
interest were incubated in TTBS buffer [0.05% (w/v) Tween 20, 150 mM NaCl, 20 mM 
Tris-HCl, pH 7.5, supplemented with 1% (w/v) BSA] for 1 h at room temperature, and 
then with the primary antibody (CD38, 1:1000; CD10, 1:250; CD19, 1:500 in the same 
buffer) for overnight incubations at 4 °C. The primary antibodies were then removed and 
the strips were washed twice in TTBS, for 10 min each. The strips were incubated for 1 
h at room temperature with the HRP-conjugated anti-mouse secondary antibody 
(1:5,000 in TTBS buffer), washed twice in TTB for 10 min each, and twice in TBS 
buffer (150 mM NaCl, 20 mM Tris-HCl pH 7.5). After washing, the strips were 
processed for ECL-based detection, according to the ECL reagents manufacturer 
instructions. 
3.10  Flow Cytometry  
Flow Cytometry is a biophysical technology employed to measure and analyse multiple 
physical and chemical characteristics of single particles, usually cells in liquid samples, 
as they flow in a fluid stream through a light beam.   
A flow cytometer is made up of three main systems: fluidics, optics, and electronics. 
 The fluidics system transports particles in a stream to the laser beam for the 
detection. 
 The optics system consists of one or more lasers to illuminate the particles in the 
sample stream and optical filters to direct the resulting light signals to the 
appropriate detectors. 
 The electronics system converts the detected light signals into electronic signals 
that can be processed by the computer.  
A flow cytometer is able to analyse any suspended particle or cell (from 0.2 to 150 um) 
and can measure important features including size, granularity or internal complexity, 
and relative fluorescence intensity.  In the flow cytometer a laser beam (usually a 488nm 
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Argon ion laser) is directed onto a stream of fluid; when particles pass through the laser 
beam, they scatter laser light. A number of detectors are placed at the point where the 
stream passes through the light beam: a detector in line with the light beam (Forward 
Scatter or FSC) and several ones perpendicular to it (Side Scatter (SSC) and one or more 
fluorescent detectors (FL-1, FL-2, FL-3 and so on) (Figure 23). 
 
Figure 23: Working diagram of a flow cytometry system. 
The detectors collect the scattered and fluorescent light and it is then possible to obtain a 
lot of information about the physical and chemical structure of each individual particle 
[93][94].  
Forward Scatter light (FSC) is proportional to cell-surface area or size and represents 
mostly the diffracted light. Side-scattered light (SSC) is proportional to cell granularity 
or internal complexity and represents mostly the refracted and reflected light that occurs 
at any interface within the cell (SSC detector is at 90 degrees to the laser beam). 
Correlated measurements of FSC and SSC can allow for differentiation of cell types in a 
heterogeneous cell population. Major leucocyte subpopulations residing in human 
peripheral blood can be differentiated using FSC and SSC (Figure 24). 
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Figure 24: Leucocytes differentiation by FSC and SSC signals. 
The ability of flow cytometry to distinguish different cellular populations is the reason 
why it is routinely used in the diagnosis of health disorders, especially blood cancers, 
but has many other applications in basic research, clinical practice and clinical trials [95]. 
In the next section, I will show the protocol used for flow cytometry analysis on 
leukemia cells. These procedures were performed at the IRCCS SDN laboratory, in 
Naples. 
3.10.1 Sample preparation 
RS4;11, REH and MN60 cell lines, 2 x10
5
 cells were diluted in 100 μL of DPBS buffer 
supplemented with 1% BSA and incubated at 4°C for 30 min with appropriate amount of 
monoclonal antibodies, following the manufacturer instructions (provided by Beckman-
Coulter). The combination of antibodies used are: i) anti-CD20 Fluorescein 
isothiocyanate with anti-CD19 Phycoerythrin; and ii) anti-CD10 Phycoerythrin with anti 
CD38 Phycoerythrin;-Cy7. All antibodies for flow cytometry analysis were provided 
from Beckman-Coulter. After incubation with these monoclonal antibodies, the cells 
were washed in DPBS with 1% BSA and diluted in 500 μL of the same solution for flow 
cytometry acquisition. At least 20.000 events were recorded for each experimental point 
on a FC-500 flow cytometer (Beckman-Coulter). Cells stained with irrelevant 
monoclonal immunoglobulin reagents conjugated with the same fluorochromes were 
used as negative controls.  
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4 
Diagnosis and classification 
of B-ALL cells 
Acute lymphoblastic leukemia (B-ALL) is a neoplastic disorder that shows high 
mortality rates due to immature lymphocyte B-cell proliferation. B-ALL diagnosis 
requires identification and classification of the leukemia cells. Here, I will describe the 
use of Raman spectroscopy to discriminate normal lymphocytic B-cells from three 
different B-leukemia transformed cell lines (i.e., RS4;11, REH, MN60 cells) based on 
their biochemical features. In combination with immunofluorescence and Western 
blotting, I will show that these Raman markers reflect the relative changes in the 
potential biological markers from cell surface antigens, cytoplasmic proteins, and DNA 
content and correlate with the lymphoblastic B-cell maturation/differentiation stages. 
4.1 Introduction 
Acute lymphoblastic leukemia type B (B-ALL) is a hematological malignancy that is 
characterized by uncontrolled and rapid cell proliferation of immature B-cell progenitors 
(i.e., lymphoid or lymphoblastic cells) that cannot mature properly into lymphocytic B 
cells [1][2]. Thus, its timely and accurate diagnosis is fundamental for successful clinical 
treatment.  
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A firm diagnosis of B-ALL requires first the identification of the leukemia cells, and 
second their classification based on the differentiation/maturation stage in which the 
lymphoblastic B cells are blocked, as above described (paragraph 1.3.1): 
(i) L1 blasts, with small and homogenous cell size, high nuclear/cytoplasmic 
ratio, and unclear nucleoli;  
(ii) L2 blasts, with medium cell size, lower nuclear/cytoplasmic ratio, with one 
or more visible nucleoli; and  
(iii) L3 blasts, with larger and pleomorphic cell size, prominent nucleoli, and 
abundant cytoplasm.  
However, in some cases of poorly differentiated B-ALL, morphological assessment 
provides low sensitivity and equivocal results [3]. Although most cases can be 
diagnosed by this method, there is only a modest correlation between morphological 
categories, treatment responsiveness, and prognosis [3].  
As a consequence, this morphological approach can be combined with 
immunophenotypic B-ALL cell analysis of the arrested stage of B-cell maturation in 
terms of the surface expression of up to six to eight different B-cell–associated antigens 
by multi-parametric flow cytometry, as above quoted (paragraph 1.3.2) [25][26][27][28].  
However, this immunophenotypic analysis requires a panel of antibodies against several 
lymphoid-expressing antigens, and it is labor intensive and time consuming. Moreover, 
the use of fluorescent dyes is frequently limited by photobleaching of the dye molecule, 
the limited ability to detect multiple dyes, and interference with the fluorescence of the 
routine stains used in the cell morphology assessment [29]. Therefore, new approaches 
are required for rapid and sensitive diagnosis, classification, and prognosis of leukemias.  
In the present chapter, I will demonstrate that RS can be used to identify and classify 
three B-leukemia cell types that closely mimic the different differentiation/maturation 
stages of B-ALL cells (i.e., RS4;11, REH, MN60 cells) versus their normal B-cell 
counterparts.  
4.2 Morphological and immunophenotypic identification 
and classification of B-ALL cells  
The first two cell models that I used were originally derived from patients with B-ALL: 
the RS4;11 and REH cell lines, which are both classified as the L2-blast (i.e., B-cell 
precursor leukemia) subtype [81][82][83][113][114]. The third cell model was the 
MN60 cell line, which represents a more differentiated B-ALL cell type, as it is 
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classified as the L3-blast (i.e., B-cell leukemia) subtype [115][116][117]. To define 
these cell lines further, I initially carried out immunophenotypic and morphological 
characterization of the expression profiles of the sequential plasma-membrane antigens 
of these cell lines, as summarized in Figure 25.  
 
Figure 25: Differentiation scheme and morphology of the RS4;11, REH and MN60 B-
leukemia cell lines. (a) Immunophenotypic profile with the coordinate and sequential well-
characterized plasma-membrane antigen expression. (b) Morphologic features and 
immunophenotypic expression pattern. (c) Representative images of the cell morphology using 
May Grunwald-Giemsa histochemical staining for DNA and RNA molecules. Scale bar: 10 μm. 
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Thin-layer of the RS4;11, REH and MN60 B-leukemia cells for morphological analysis 
were prepared using a cytocentrifuge (Thermo Scientific Shandon Cytospin4; Thermo 
Fisher Scientific Inc, USA) according to manufacturer instructions, and then stained 
using the May-Grunwald-Giemsa staining protocol (SIGMA-Aldrich, St. Louis, MO, 
USA). The cells were then examined under light microscopy at 40× magnification for 
the morphological analysis. The RS4;11 and REH B-leukemia cells showed small to 
medium nuclear size, with a regular shape, finely dispersed chromatin, and one or more 
nucleoli. The cytoplasm was scanty, with slight or moderate staining and variable 
vacuolation. Instead, the MN60 B-leukemia cells showed medium to large nuclear size, 
with an irregular and lobulated shape, finely stippled chromatin, and two or more 
prominent nucleoli. There was moderately abundant cytoplasm, with prominent 
vacuolation and very deep staining, typical of the L3 subtype B-ALL cells (Figure 25b-
c). 
 
Figure 26: Identification and classification of acute lymphocytic leukemia cells.  
(a) Representative confocal microscopy images of RS4;11, REH and MN60 B-leukemia cells 
fixed and processed for immunofluorescence analysis with anti-CD38, anti-CD19, anti-CD10 
and anti-CD20 monoclonal antibodies (red), to monitor their expression levels. Gray, Hoechst-
33258 nucleic-acid staining. Scale bar: 10 μm. (b) Representative immunoblotting of RS4;11, 
REH and MN60 cells with antibodies against CD10, CD19, CD20 and CD38 (as indicated). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown for the internal protein levels 
and molecular weight standards (kDa) are indicated on the left of each panel. The blots have 
been run under the same experimental conditions.  
Using the well-defined quadruple CD38/ CD19/ CD20/ CD10 staining for leukemia 
cells [118][119], I first examined these cells under confocal fluorescence microscopy 
and by Western blotting (Figure 26). CD38 and CD19 were expressed on the surface of 
the plasma membranes of all of these three cell lines, and their expression increased for 
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the different differentiation stages from RS4;11 and REH cells to MN60 cells. CD20 
was expressed only on the plasma membranes of the more differentiated MN60 cells 
[1][117] (Figure 26Errore. L'origine riferimento non è stata trovata.). Finally, CD10 
expression increased for the differentiation from RS4;11 to REH, and then decreased in 
MN60 cells, as already described for the L2-blast and L3-blast subtypes [1][117]. These 
immunophenotypic analyses validated the RS4;11 and REH cells as a model for the L2 
subtype and the MN60 cells as a model for the L3 subtype of B-ALL cells. 
4.3 B-cell purity assessment  
The purity of the B-cells was measured using flow cytometry after the cells had been 
stained with a fluorochrome-conjugated antibodies mix composed of: anti-CD45 (pan-
leucocyte marker) conjugated with fluorescein isothiocyanate; anti-CD56 (natural killer 
cell marker) conjugated with Rodamine-1; anti-CD19 (B-cell marker) conjugated with 
phycoerythrin-Texas Red conjugate; and anti-CD3 (T-cell marker) conjugated with 
phycoerythrin-cyanine5 tandem. These antibodies were from Beckman-Coulter. The 
fluorescence intensities were measured with a flow cytometer (FC-500; Beckman-
Coulter, Milan, Italy), according to the manufacturer instructions. Forward scatter and 
side scatter gates were established to exclude dead cells and cell debris. The percentage 
of B-cells (CD19+/CD45+), T-cells (CD3+/CD45+) and NK-cells (CD56+/CD45+) 
were assessed before the immunomagnetic procedure, as shown in Figure 27a, c and e, 
respectively. The percentage of B-cell enrichment was verified after the 
immunomagnetic separation procedure, according to Figure 27b. Contamination by T-
cells and NK-cells was also determined (Figure 27d and f, and it was always negligible 
(<1.0%).  
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Figure 27: Dot plots for the determination of human B-lymphocyte purification by flow 
cytometry. The percentage of B-cells (a, b, CD19+/CD45+, red events), T cells (c, d, 
CD3+/CD45+, blue events), and natural killer (NK) cells (e, f, CD56+/CD45+, green events) 
determined by flow cytometry, as pre-separation and post-separation through negative 
immunomagnetic selection. The content of the B-lymphocytes in the purified enriched fraction 
was routinely about 98% (as indicated) in all of the samples analyzed.  
4.4 Preliminary Raman spectra reproducibility analysis 
Spectra obtained from nucleus, cytoplasm and membrane of the studied cells (B-cells 
and RS4;11, REH and MN60 B-leukemia cells) were preliminary analyzed. Figure 28 
shows MN60 nucleus, cytoplasm and membrane spectra. The spectra have been 
calculated by acquiring three different spectra from the nucleus, cytoplasm and 
membrane within a cell and repeating the measurements on 20 different cells. The three 
spectra contain specific features for those regions of the cells, providing an intrinsic 
check for the region inside a cell from where the spectrum was obtained. However, no 
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qualitative differences were observed between spectra obtained from different cells or 
different nucleus, cytoplasm and membrane regions within a cell. 
Moreover, it was possible to detect differences in the biochemical composition between 
nucleus, cytoplasm and membrane regions. The Raman spectrum of nucleus showed 
significant spectral features previously assigned to nucleic acid contributions such as the 
ring breathing modes of the nucleic acid bases (730 cm
-1
 adenine ring breathing, 780 cm
-
1
 uracil, cytosine and thymine ring breathing, 1120 cm
-1
, 1370 cm
-1
 and 1578 cm
-1
 
guanine and adenine contributions) and from the O-P-O backbone (788 cm
-1
 and 1095 
cm
-1
) (Figure 28b - gray band). Additionally, the Raman spectrum of cytoplasm is 
characterized by intense vibrational bands in the spectral region around 1300-1350 cm
−1
 
and 1400-1500 cm
−1
 (Figure 28b - cyan band) that have contributions from proteins and 
to a minor extent also from carbohydrates. The noisier Raman spectrum of membrane 
reveals strongest Raman peaks of lipids that are present at 1449 cm
-1
, 1301 cm
-1
 (CH 
vibrations) and 1660 cm
-1
 (C=C stretching) and belong to vibrations of the hydrocarbon 
chains.  
The position of the laser, during acquisition, was focused on the cell nucleus, as this is 
where the most relevant information is likely to originate, although with large volume, 
the system should also partially examine the membrane and cytoplasm above and below 
the nucleus. However, in the nuclear region slightly differences (about 5%) in the 
intensity ratio I1447/I785 (representative of protein-DNA ratio) were found (Figure 28c).  
 
Figure 28: (a) Representative optical image of MN60 B-leukemia cell. The Raman probe 
location during the spectra acquisition is also shown. Scale bar: 10 μm.  (b) Mean Raman 
spectra of nucleus, cytoplasm and membrane of MN60 B-leukemia cells. Each spectrum is an 
average of 60 acquisitions. (c) Intensity ratio of the Raman signals at 1447 cm
-1
 and 785 cm
-1
.  
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A comparison of bright field image and false colour Raman image of MN60 B-leukemia 
cell is shown in Figure 29.  
Before the Raman imaging, the sample was fixed with 0,4% paraformaldehyde (PFA) 
and was successively washed with PBS; for the Raman measurements, 1x10
6
 cells were 
suspended in 500 μl of PBS and coated onto quartz slides.  
Raman image of the cell was recorded with an inverted confocal Xplora microscope 
(Horiba, Jobin Yvonne) equipped with a 600 gr/mm grating. The Raman signal was 
excited with a 532 nm diode laser, focused onto the cell through a 60x water immersion 
objective (Nikon, Ti-2000 Eclipse, NA = 1.2) and with a power of about 5 mW in the 
object plane. The Raman image was recorded by raster scanning the cell (square area 15 
x 15 μm) trough the laser focus, with a step size of 0.4 μm, and acquiring a full spectrum 
(integration time of 0.5 s) at each position. A total of 2500 spectra were collected in 
almost 30 minutes. Specific spectral regions were used to reconstruct the false colour 
Raman map reported in Figure 29. Raman images in the spectral region between 700-
800 cm
-1
 (in red) overlaps with the nuclear region of the cell, as visible by the 
comparison with the bright filed image of the MN60 cell. This indicates a significant 
presence of nucleic acids in this area. Raman map in the spectral region between 2800 
cm
−1
 and 3000 cm
−1
 (in yellow) overlaps with cytoplasmic vesicle content. This is not 
surprising since vesicle are reach in phospholipids. The cell membrane Raman map (in 
blue) is additionally shown in Figure 29.  
 
Figure 29: Bright field image (left) and reconstructed Raman image (right) of a MN60 B-
leukemia cell. Nucleic acid and proteins content is represented in red colour, the cytoplasmic 
vesicles in yellow colour. The blue colour corresponds to the background (extracellular region).  
Scale bar: 5 μm. 
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4.5 Raman identification and classification of B-ALL cells 
To evaluate the RS signatures that might specifically identify differences in the 
biochemical compositions of these L2 and L3 B-leukemia cells versus their normal B-
cell counterpart purified from human peripheral blood, I acquired Raman spectra from 
these RS4;11, REH and MN60 transformed B-leukemia cells and from B lymphocytes 
(Figure 30) [120]. More than three hundred spectra for each cell type were recorded and 
evaluated.  
 
Figure 30: Identification and classification of acute lymphocytic leukemia cells.  
(a) Mean Raman spectra of normal B lymphocytes and the three analyzed B-leukemia cell lines 
(as indicated). Each spectrum is an average of 300 cells. (b) Raman spectral classification and 
assignment [22][23]. Abbreviations: def, deformation; str, stretching; bk, vibration of 
backbone; sym, symmetric; A, adenine; C, cytosine; G, guanine; T, thymidine; U, uracil (ring 
breathing modes of DNA/RNA bases); Phe, phenylalanine; Tyr, tyrosine; Trp, tryptophan; NA, 
nucleic acids, P, proteins; L, lipids. 
The Raman spectrum of lymphocyte B-cells (Figure 30a) contained spectral features of 
DNA and RNA that arose from the individual bases (i.e., adenine, thymine, cytosine, 
guanine, uracil), as well as from the sugar-phosphate backbone of DNA (a, gray region; 
700-800 cm
-1
, 1120 cm
-1
, 1370 cm
-1
, 1577 cm
-1
). The RS features of lipids arose from 
the stretching of the various CH2 and CH3 groups (Figure 30a, green region; 1150-1250 
cm
-1
). The RS features of proteins included contributions from the amide groups of the 
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secondary protein structures (e.g., α-helices, β-sheets, random coils), aromatic amino 
acids (e.g., tryptophan, tyrosine, phenylalanine), and stretching or deformation of carbon 
atoms bonded with hydrogen, nitrogen, and other carbon atoms (Figure 30a, cyan 
region; 1000 cm
-1
, 1300-1350 cm
-1
, 1400-1500 cm
-1
, 1600-1650 cm
-1
) [121]. The 
assignment of the Raman peaks is given in Figure 30b [106][120]. To identify the most 
important spectral differences, the spectra of the B-leukemia RS4;11, REH, and MN60 
cells were directly compared to those of the normal B lymphocytes (Figure 30a), and 
their spectral differences were calculated (Figure 31).  
This comparison revealed that these three transformed B-leukemia cell lines showed 
Raman spectra that were similar to the normal B-lymphocyte counterpart, although with 
significantly different mean intensities for some specific peaks. The spectra obtained 
showed negative differences around 785 cm
-1
, 1370 cm
-1
, and 1577 cm
-1
, which are due 
to the ring breathing modes in the DNA bases [17][106][120] and near 1120 cm
-1
, which 
is due to the symmetric PO2− stretching vibration of the DNA backbone [17][106][120] 
(Figure 31). Additionally, the MN60 Raman spectra revealed higher intensity of the 
peak around 743 cm
-1
, which is generally assigned to RNA bases [13][106][120] (Figure 
31). Positive difference peaks were also seen at 1420-1485 cm
-1
 (CH proteins/ lipids), 
1310 cm
-1
 (amide III band), 1337 cm
-1
 (CH proteins/ nucleic acids), 1607-1617 (C=C 
vibrations), and 1650 cm
-1
 (amide I band) [13][17][106][120][122] (Figure 31). It can 
also be noted that the magnitudes of these changes generally appeared more pronounced 
from the RS4;11 to the MN60 cells (Figure 31). Therefore, the intensity variations in 
these specific Raman peaks appear to correlate well with the differentiation/maturation 
stages of these B-leukemia cells. 
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Figure 31: Difference spectra between acute lymphocytic leukemia cells and normal B-cells.  
4.6 Principal component analysis for the Raman spectra 
To define the efficiency and sensitivity of the proposed approach for single-cell cancer 
diagnosis and classification, I combined the RS analysis with a multivariate statistical 
method: PCA [123]. In the spectral range from 600-1800 cm
-1
, each Raman spectrum 
consists of 1200 variables at 1 cm
-1
 spacing; however, only a fraction of these contain 
useful information for this cell classification. PCA was performed on the spectral data to 
define the new dimensional space in which the major data variance can be detected and 
represented by a few relevant parameters, known as the principal components (PCs). 
These PCs form a model through which the RS signal of individual cells can be assigned 
a score. Therefore, PCA can provide a chart of the PCA scores of individually analyzed 
cells where similar Raman spectra cluster together [13][120][121][123][124]. Indeed, 
the combination of RS with several multivariate statistical methods has been 
successfully applied to discriminate between healthy and cancerous tissues, as well as 
between healthy and tumorigenic cells [13][15][120][121][124].  
Here, the first three PCs (PC1-3) accounted for close to 98% of the total variance, and so 
I used these to generate scatter plots, where the clusters of points represented different 
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cell groupings (Figure 32a). The significance of these selected PCs was initially 
evaluated in an analysis of the loading values, where they showed the largest deviations 
from zero. This PCA analysis shows that when PC2 and PC3 were plotted against PC1, 
these three B-leukemia cell types and the normal B-lymphocyte counterpart formed four 
distinct and well-defined groups (Figure 32a). The main result of this statistical analysis 
was then the creation of the confusion matrix that corresponds to the leave-one-out 
predictive classification for these normal and leukemia cells (Figure 32b) [124]. Here, 
the diagonal values of this confusion matrix indicate that 1167 out of 1200 cases were 
classified correctly, which thus resulted in an efficiency of 97.3%. 
 
Figure 32: Identification and classification of acute lymphocytic leukemia cells.  
(a) PCA scatter plots comparing control B lymphocytes and B-leukemia cells. (b) Confusion 
matrix for the classification of the control B lymphocytes and the B-leukemia cells. 
4.7 Discussion and conclusions 
This experimental chapter demonstrates the potential application of RS to the 
identification of three transformed leukaemia cell lines:  RS4;11, REH and MN60 cells 
[1][114]. RS4;11 and REH B-leukemia cells are representative of the L2 B-ALL subtype, 
and the MN60 B-leukemia cells are representative of the L3 B-ALL subtype, the Raman 
spectra here reported clearly highlight these differences. For instance, the relative peak 
intensities at 785 cm
-1
, 1120 cm
-1
, 1370 cm
-1
, and 1577 cm
-1
 (related to DNA bases) 
were lower in these B-leukemia cells compared to normal B-lymphocytes, which 
indicates a reduction in the nucleic-acid content of the cells. This effect might be due to 
breaks in and translocations of several chromosomes (e.g., in REH cells, the X-
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chromosome is completely missing [125]) or to chromatin decondensation [126]. Of 
note, the Raman spectrum of the MN60 B-leukemia cells was slightly different from 
those of both the RS4;11 and REH B-leukemia cells, which also confirmed that these 
MN60 B-leukemia cells can be classified as a distinct B-leukemia cell subtype, as 
indeed is the case based on its more differentiated maturation stage. The Raman 
spectrum for the MN60 B-leukemia cells showed greater intensity of the peak around 
743 cm
-1
, which would appear to be due to an increase in ribosomal RNA content, which 
in turn correlates with higher synthesis and content of proteins. Indeed, the 
morphological assessment of these MN60 B-leukemia cells showed intense cytoplasmic 
staining that is indicative of the presence of large amounts of ribosomal RNA in the 
rough endoplasmic reticulum where the biosynthesis of immunoglobulins and other 
proteins takes place [82][127]. In addition, there were relative increases in the Raman 
spectra intensities for the bands related to amide III (1310 cm
-1
), amide I (1650 cm
-1
), 
and CH/CC (1337, 1420-1485, 1607-1617 cm
-1
) proteins, which correlated with the 
protein structure in these three B-leukemia cell lines. The magnitudes of these peaks 
increased from the RS4;11 cells to the MN60 cells, in agreement with the extent of 
expression of plasma-membrane antigens, nucleus/cytoplasm ratio and cytoplasmic 
immunoglobulins during the B-cell differentiation/maturation process. I also explored 
PCA here, together with a leave-one-out cross-validation approach, for B-leukemia cell 
identification and classification [119], which provided a diagnostic efficiency of 97.3% 
for separating B-leukemia versus normal B-lymphocytes. The PCA also indicated larger 
spread of the normal B-cell cluster compared to the populations of B-leukemia cells, 
which was probably due to greater cell-to-cell variation for the different donors of the 
normal B-lymphocytes. Additionally, the MN60 cluster was completely separated from 
the others, which again confirms that this model system is more differentiated.   
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5 
Follow-up after chemotherapeutic 
treatment of B-ALL cells  
This study demonstrates the potential of the Raman technique for the identification of 
key biochemical changes of leukemia cells under chemotherapeutic treatments. 
In this chapter, I will describe the use of RS to analyze the biochemical features of the B-
leukemia cell lines (RS4;11, REH and MN60) after low-dose and noncytotoxic 
treatments with methotrexate (MTX) and 6-mercaptopurine (6MP), the two key drugs 
used in current B-ALL maintenance therapy.  
To identify specific RS peaks that correlate with the different stages of these B-leukemia 
cells, I defined the spectral changes after these B-ALL therapies in comparison with 
those seen under all-trans-retinoic acid (ATRA) treatment (used in the treatment of a 
different leukemia disease). Principal component analysis (PCA) was used to confirm 
the significance of these Raman spectral markers in the detection of minimal residual 
disease.  
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5.1 Immunophenotypic analysis of B-ALL regression 
after low-dose maintenance therapy 
 
Figure 33: Acute lymphocytic leukemia regression through low-dose of MTX.  
(a) Representative confocal microscopy images of RS4;11, REH and MN60 B-leukemia cells 
treated with 1 μM MTX for 72 h to mimic the clinical B-ALL maintenance therapy. Cells were 
fixed and processed for immunofluorescence analysis with anti-CD38, anti-CD19, anti-CD10 
and anti-CD20 monoclonal antibodies (red) to monitor their expression levels. Gray, Hoechst-
33258 nucleic-acid staining. Scale bar: 10 μm. (b) Representative immunoblotting of RS4;11, 
REH and MN60 B-leukemia cells treated as in a, with antibodies against CD10, CD19, CD20 
and CD38 (as indicated). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown for 
the internal protein levels and molecular weight standards (kDa) are indicated on the left of 
each panel. The blots have been run under the same experimental conditions. 
To provide a scenario as close as possible to the clinical setting, I analyzed the specific 
spectral variations of the cells under ‘treatment’ with two clinically demonstrated 
beneficial drugs that are used in maintenance chemotherapy of patients with B-ALL: 
MTX and 6MP. Low doses of MTX and 6MP that provide patients with peak plasma 
concentrations range from 0.01 µM to 1 µM [128] are used to induce specific B-ALL 
regression. MTX and 6MP are also specific treatments for patients with B-ALL, as they 
do not provide benefits for other leukemias, such as for regression of acute 
promyelocytic leukemia, where the maintenance therapy is primarily ATRA [128]. 
These three transformed B-leukemia cell lines were thus treated for 72 h with 1 µM 
MTX, 1 µM 6MP, or 1 µM ATRA (as the control) [41]. The cells were then analyzed by 
immunofluorescence microscopy and Western blotting to determine whether the B-ALL 
regression obtained in patients under similar conditions is associated with decreased 
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expression of particular B-leukemia antigens. This MTX treatment significantly reduced 
the plasma membrane staining of CD38 and CD19 in all of these B-leukemia cell lines, 
along with that of CD10 in the REH and MN60 cells, and of CD20 in the MN60 cells 
(Figure 33a versus non-treated control cells shown in Figure 26a). These 
immunofluorescence data were supported and confirmed by Western blotting (Figure 
33b). Moreover, reduced intensity of nucleic-acid fluorescence staining was also 
observed in all three of these MTX-treated B-leukemia cell lines (Figure 33a versus non-
treated control cells shown in Figure 26a). 
Similar data for both antigen expression and nucleic acids (stained with Hoechst dye) 
were obtained with 6MP treatment (data not shown), while no effects were detected with 
ATRA treatment (Figure 34). 
 
Figure 34: Effect of ATRA treatment on Acute lymphocytic leukemia cells.  
(a) Representative confocal microscopy images of RS4;11, REH and MN60 B-leukemia cells 
treated with 1 μM ATRA for 72 h, and fixed and processed for immunofluorescence analysis with 
anti-CD38, anti-CD19, anti-CD10 and anti-CD20 monoclonal antibodies (red) to monitor their 
expression levels. Gray, Hoechst-33258 nucleic-acid staining. Scale bar: 10 μm. (b) 
Representative immunoblotting of RS4;11, REH and MN60 B-leukemia cells treated as in a, with 
antibodies against CD10, CD19, CD20 and CD38 (as indicated). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) is shown for the internal protein levels and molecular weight 
standards (kDa) are indicated on the left of each panel. The blots have been run under the same 
experimental conditions. 
Flow Cytometry analysis confirmed confocal microscopy study regarding the down-
regulation of CD19, CD10 and CD38 differentiation antigens upon induction with MTX, 
while no effects were detected with ATRA treatment (Figure 35). 
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Figure 35: Flow cytometry analysis of RS4;11, REH and MN60 cell lines. Panel A shows 
dot-plots analysis for the CD20 and CD19 surface expression on RS4;11, REH and MN60 cell 
lines in untreated conditions (Panel A, Upper Line), or treated for 72h with 1 μM of MTX (Panel 
A, middle line), or treated for 72h with 1 μM of ATRA (Panel A, bottom line). Panel B displays 
dot-plots analysis, for the CD38 and CD10 surface expression on RS4;11, REH and MN60 cell 
lines treated as in panel A.  
These preliminary analyses indicate that MTX treatment specifically reverted the B-cell 
differentiation process for these L2 (RS4;11 and REH cells) and L3 (MN60 cells) 
subtypes of B-leukemia cells (Figure 33), while as expected, the ATRA acute 
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promyelocytic leukemia treatment had no effect (Figure 34). Of note, under these 
conditions, no drug-mediated apoptotic effects were detected, as indicated by the 
nucleolus and chromatin staining with the Hoechst 33258 dye (Figure 33a, Figure 34a) 
[129].  
5.2 Raman analysis of B-ALL regression after low-dose 
maintenance therapy 
Figure 36 shows the comparison of the mean Raman spectra of these B-leukemia 
RS4;11, REH, and MN60 cells before and after the 1 µM MTX treatment, and the 
difference spectra obtained by subtraction of the MTX-treated spectra from the untreated 
cell spectra. The MTX-treated cells showed lower Raman intensities of the peaks related 
to nucleic acids, as can be seen at 785 cm
-1
, 1120 cm
-1
, 1370 cm
-1
, and 1577 cm
-1
. These 
reductions in the Raman bands suggest that the levels of nucleic acids are lower after the 
chemotherapy in these B-leukemia cells. Interestingly, the Raman spectra of the 6MP-
treated B-leukemia cells showed similarly lower Raman intensities of the peaks related 
to nucleic acids as seen for the MTX-treated cells (Figure 37). As well as these peaks, 
the MTX-treated and 6MP-treated cells showed lower peak heights in the bands at 1004 
cm
-1
 (CC ring breathing mode of phenylalanine) and 1447 cm
-1
 (CH2 deformation mode 
of proteins). The intensity of 1447 cm
-1
 Raman band is insensitive to the protein 
structure and depends only on the number of proteins, which indicated that these MTX 
and 6MP treatments induced specific reductions in the cell protein content [129]. 
Conversely, the ATRA-treated cells did not show reduced expression of CD10, CD19, 
CD20, and CD38 at the plasma membrane and nucleic-acid fluorescence staining 
intensity (Figure 34), and in turn, did not show significant modifications in the Raman 
spectral region related to protein-DNA ratio (around  1447 and 785 cm
-1
; Figure 38). In 
general, the difference spectra between the ATRA-treated and nontreated B-leukemia 
cells show only slight spectral variations. 
These specific spectral modifications should be explained by the mechanisms of action 
of the chemotherapeutic drugs used in this study. The reduced nucleic acid content can 
be explained by the inhibition of the enzyme dihydrofolate reductase through MTX-
derived metabolites [130]. The dihydrofolate reductase inhibition arrests the synthesis of 
both purines and thymidine, which alters DNA replication and RNA synthesis, and thus, 
in turn, the nucleic acid cell content. Similarly, the mechanism of action of 6MP consists 
of inhibition of the de-novo pathway for purine ribonucleotide synthesis [131] that is 
required for DNA repair, methylation, and mitotic duplication. On the other hand, the 
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reduced protein content can be explained by the decreased expression of plasma 
membrane antigens (e.g., CD10, CD19, CD20, CD38) and cytoplasmic 
immunoglobulins. Interestingly, both MTX and 6MP treatments similarly affected the 
Raman spectra of these three B-leukemia cells, with reduced intensities of peaks related 
to DNA, RNA and protein content. To demonstrate the specific ability of this RS 
approach for the detection of the anti-leukemic effects of MTX and 6MP treatments on 
these B-leukemia cells we used ATRA treatment as a control. The Raman spectra of the 
ATRA-treated and nontreated B-leukemia cells did not show any significant differences. 
Indeed, the relative variations in the Raman band intensities were much smaller than 
those observed between normal B-lymphocytes and the B-leukemia cells, or between 
MTX-treated or 6MP-treated and nontreated B-leukemia cells. 
 
Figure 36: Acute lymphocytic leukemia regression through low-dose of MTX.   
Raman spectra of three B-leukemia cell lines recorded without and with MTX treatment as in a. 
The difference spectra were obtained by subtracting the untreated from the treated spectra 
(bottom panels).  
 
Figure 37: Acute lymphocytic leukemia regression through low-dose of 6MP. 
Raman spectra of the three B-leukemia cell lines recorded without and with 1 μM 6MP for 72 h. 
The difference spectra obtained by subtracting the B-leukemia cell spectra from the 6MP-treated 
B-leukemia cell spectra are also shown (bottom panels). 
Figure Sup2  Managò et al.
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Figure 38: Effect of ATRA treatment on Acute lymphocytic leukemia cells. 
Raman spectra of three B-leukemia cell lines recorded without and with ATRA treatment as in a. 
The difference spectra were obtained by subtracting the untreated from the treated spectra 
(bottom panels). 
To further highlight the ability of RS to specific follow the drug-induced biochemical 
changes in leukaemia cells, I additionally analysed the spectral changes of the 
considered cell lines (RS4;11, REH and MN60 cells after low-dose and noncytotoxic 
treatments with methotrexate (MTX) at three different concentrations (0.01 µM, 0.1 µM 
and 1 µM). 
 
Figure 39: Effect of MTX-treatment at concentration of 0.01, 0.1 and 1 µm on MN60 cells. 
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Figure 39 shows the mean Raman spectrum of MN60 cells before MTX treatment and 
the Raman spectra of MN60 after the MTX treatment at three different concentrations. 
The MTX-treated cells showed a gradual decrease of intensities of Raman peaks related 
to nucleic acids (785 cm
-1
, 1120 cm
-1
, 1370 cm
-1
, and 1577 cm
-1
) and, similarly, a 
progressive decrease of Raman bands related to proteins (1004 cm
-1
, 1300-1350 cm
-1
, 
1400-1500 cm
-1
); these reductions in the Raman bands are proportional to the increase of 
MTX concentrations, from 0.01 µM to 1 µM.  
These findings confirm that very specific Raman markers can be used to discriminate 
normal from both leukemia cells and leukemia cells under maintenance treatment, which 
suggests that RS can be used in the detection of minimal residual disease. 
5.3 PCA analysis of B-ALL regression  
Finally here, I used PCA to evaluate the discrimination between the drug-treated versus 
the normal B cells according to the RS. Figure 40a shows the PCA scatter plots of the 
scores of PC1-3 of 300 of each of the control B cells and MTX-treated B-leukemia 
RS4;11, REH and MN60 cells. The control B cells can be easily distinguished from the 
MTX-treated B-leukemia cells by this PCA, as shown by the distinct group of the B 
lymphocytes. The data reported in the confusion matrix (Figure 40b) indicate that 1172 
out of 1200 of these cells were correctly classified, which gives an efficiency of 98.8%. 
Similar data were obtained with the 6MP-treated leukemia cells. On the other hand, by 
comparing the Raman spectra of the B-leukemia cells to those of the ATRA-treated B-
leukemia cells using PCA, there was large overlap according to the PC1 versus PC2 
plots, and thus little, if any, effects of ATRA on these PCs (Figure 41). 
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Figure 40: Acute lymphocytic leukemia regression through low-dose of MTX.  
(a) PCA scatter plots comparing the untreated and MTX-treated B-leukemia cells. (b) Confusion 
matrix for the classification of the untreated and MTX-treated B-leukemia cells. 
 
Figure 41: Effect of ATRA treatment on Acute lymphocytic leukemia cells.  
(a) PCA scatter plots comparing the untreated and ATRA-treated B-leukemia cells. (b) 
Confusion matrix for the classification of the untreated and ATRA-treated B-leukemia cells. 
5.4 Discussion and conclusions 
Using independent and complementary approaches, as immunofluorescence, Western 
blotting and RS, I identified some biological features that were modified under these B-
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ALL specific maintenance therapies. Of note, low-dose treatments were used here to 
better analyze the accuracy of our approaches for the detection of these specific 
biochemical changes. In more detail, under both MTX and 6MP treatments, all three of 
these B-leukemia cell lines showed B-leukemia regression through the reversing of the 
B-cell differentiation/maturation process, which was identified and classified according 
to the specific antigen expression profiles, and promoted changes in the nucleic acid 
contents without any apoptotic effects. These specific modifications should be explained 
by the mechanisms of action of the chemotherapeutic drugs used in this study.  
Interestingly, both MTX and 6MP treatments similarly affected the Raman spectra of 
these three B-leukemia cells, with reduced intensities of peaks related to DNA, RNA and 
protein content. To demonstrate the specific ability of this RS approach for the detection 
of the anti-leukemic effects of MTX and 6MP treatments on these B-leukemia cells we 
used ATRA treatment as a control. The Raman spectra of the ATRA-treated and 
nontreated B-leukemia cells did not show any significant differences. Indeed, the 
relative variations in the Raman band intensities were much smaller than those observed 
between normal B-lymphocytes and the B-leukemia cells, or between MTX-treated or 
6MP-treated and nontreated B-leukemia cells. Additionally, the PCA scatter plots and 
the cross-validation data demonstrate that although the MTX-treated (or 6MP-treated) 
B-leukemia cells showed reduced expression of plasma membrane antigens and DNA, 
their spectra can be separated from the normal B-lymphocytes with an efficiency of 
about 99%.  
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6 
Proof of principle with B-
ALL clinical samples 
In this chapter, I will illustrate the application of RS approach to discriminate between 
normal B-lymphocytes and B-lymphocyte-enriched fractions from patients with B-ALL, 
Preliminary results from clinical samples indicate high consistency of, and potential 
applications for, this Raman spectroscopy approach. 
6.1 B-ALL clinical samples  
I extended the present study to clinical samples, with the analysis of the Raman spectra 
of B-cell–enriched lymphocyte fractions purified from peripheral blood of three patients 
with B-ALL. I preliminary analyzed these leukemic clinical cell samples using standard 
multi-parametric flow cytometry to characterize them based on the immunophenotypic 
classification (Figure 42). These leukemic cells from patients 1 (Pt-1) and 2 (Pt-2) 
showed very similar immunological features, including: plasma-membrane expression 
of CD19, CD10, CD38, and CD45 (intermediate expression level), and of HLA-DR 
antigens, with low surface expression of CD34 and no surface expression of CD20, and 
of immunoglobulins (SmIg) (Figure 42). According to this antigenic profile, these 
leukemia cells of Pt-1 and Pt-2 can both be classified as ‘common B-ALL’ and thus they 
should have similar Raman spectra to the REH B-leukemia transformed cell line. 
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Conversely, for the Pt-3–derived cells, in addition to positivity for CD19, CD10, CD38, 
CD45, and HLA-DR, there was also plasma-membrane expression of CD20, which 
indicated that their B-ALL was of a more differentiated type than for the Pt-1 and Pt-2 
cells (Figure 42). However, these Pt-3–derived cells did not express surface or cytoplasm 
immunoglobulins (Figure 42), which indicated that they might have originated from B-
cell differentiation/ maturation blocked at an intermediate process between the pro-B 
and the pre-B maturation stages. Thus, according to this immunological feature, the 
leukemic cells from Pt-3 should have a Raman spectrum with a profile in-between that 
of the B-leukemia REH and MN60 transformed cell lines.  
 
Figure 42: Immunophenotypes of the B-ALL cells from patients. The Pt-1 and Pt-2 B-ALL 
cells show a ‘common’ B-ALL immunoprofile due to the surface expression of CD19, CD10, 
CD38, CD45 (intermediate expression level, dim) and HLA-DR, with low surface expression of 
CD34 (low) and absence of CD20, and surface Immunoglobulins (SmIg). The Pt-3 B-ALL cells 
were more differentiated than those from Pt-1 and Pt-2, due to the surface membrane presence 
of CD20 with CD19, CD10, CD38 and HLA-DR, as well as bright intensity of expression for 
CD45.  
6.2 Raman diagnosis of B-ALL clinical samples  
Figure 43a shows the Raman spectra of normal B cells, the B-leukemia REH cells, and 
those acquired from the three cell samples from the patients with B-ALL. The mean 
Raman spectra of Pt-1 and Pt-2 cells appear to be similar to each other and similar to the 
Raman spectrum of the REH cells. Conversely, as illustrated in Figure 43b, there were 
distinct differences between the Raman spectrum of normal B cells and those of the 
three patient B-ALL cell samples. The peaks most exclusively related to the ring 
breathing modes in DNA bases (i.e., 785, 1120, 1370, 1577 cm
−1
) were significantly 
reduced in intensity in the Raman spectra of Pt-1 and Pt-2, while the CH2 deformation 
mode at 1447 cm
-1
 was significantly stronger (Figure 43b). These differences were more 
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pronounced in the Pt-3 Raman spectrum, as this B-ALL cell sample was more 
differentiated from the previous two.  
 
Figure 43: Proof of principle with clinical samples. (a) Mean Raman spectra from 300 
acquisitions of normal B lymphocytes, REH B-leukemia cells, and the three clinical B-ALL cell 
samples. (b) Difference spectra obtained by subtracting the normal B lymphocyte Raman 
spectrum from the clinical B-ALL samples and the REH B-leukemia cell spectra (black line).  
6.3 Statistical analysis of B-ALL clinical Raman data  
To clarify the biochemical classification and spectral variations for the B-leukemia cells, 
I used an empirical analysis based on the intensity ratio of two prominent Raman bands, 
at 1447 cm
-1
 and 785 cm
-1
 (I1447/I785). Figure 44 shows the plot of the I1447/I785 ratios 
according to the cell types. The mean (± s.d.) of the ratio for the normal B cells (RBcell 
= 1.6 ±0.3) was significantly different from the means of the B-leukemia cells (RRS4;11 = 
1.98 ± 0.17; RREH = 2.59 ± 0.18; RMN60 = 3.45 ± 0.20) and the patient-derived B-ALL 
cells (RPt−1 = 2.56 ± 0.27; RPt−2 = 2.45 ± 0.25; RPt−3 = 2.93 ± 0.27). These differences 
reflected the relative changes in the potential biological markers from cell surface 
antigens, cytoplasmic proteins, and DNA content [129]. Additionally, the spectral 
variability measured in the clinical samples was much higher compared to the B-
leukemia cell lines. The overall spectral intensities varied by 20% about the mean for 
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normal B cells, by 7% to 8% for the three B-leukemia cell lines, and by 10% to 12% for 
the clinical samples. The nonparametric intensity ratio provided a diagnostic sensitivity 
of 98.7% and specificity of 95.7% for separating the normal B cells and B-leukemia 
REH cells (P <0.00001).  
 
Figure 44: Empirical analysis of clinical samples. Plot of the intensity ratios of the Raman 
signals at 1447 cm
-1
 and 785 cm
-1
 (I1447/I785), as indicated.  
With the clinical samples, the measured diagnostic sensitivity and specificity for the 
intensity ratios and relative to the normal B cells were 79% and 81% for patient 1, 80% 
and 83% for patient 2, and 87% and 85% for patient 3, respectively.  
Table 6: Diagnostic sensitivity and specificity for clinical samples 
 
I also used PCA for classification of these clinical samples. These data for the normal B 
cells, the REH B-leukemia cells, and the three patient samples are shown in the scatter 
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plots of Figure 45. The PCA algorithm achieved identification of each pathological 
clinical sample with sensitivities of 88%, 89% and 94% for Pt-1, Pt-2 and Pt-3, 
respectively, and specificities of 85%, 88% and 90%, again for Pt-1, Pt-2 and Pt-3, 
respectively, which provides 5% to 10% improvements compared with the empirical 
methods using the intensity ratios. Therefore, although the spectral variability in the 
clinical samples is more pronounced compared to the B-leukemia cell lines, analysis of 
the Raman spectra allows the discrimination of the B-ALL clinical cell samples of these 
patients from the normal B cells with high sensitivity and specificity. 
 
Figure 45: PCA analysis. PCA scatter plots comparing normal B lymphocytes, REH B-
leukemia cells, and the three clinical B-ALL cell samples. 
6.4 Discussion and conclusions 
Finally, I extended the Raman approach to three clinical patient samples. Pt-1 and Pt-2 
had the preliminary classification of ‘common B-ALL’, and Pt-3 had B-ALL derived 
from malignant transformation of a B-cell progenitor that was intermediate between the 
pro-B and pre-B maturation stages. The distinctive differences in the Raman spectra 
between the normal and the clinical samples confirmed and further reinforced these 
observations.  
To develop simple but effective algorithms for differentiating B-leukemia cells from 
normal B-lymphocytes, the nonparametric empirical approach that uses peak intensity 
ratio measurements of specific Raman bands has been widely applied to evaluate 
malignant changes in several studies [132][133]. Here, I showed that the nonparametric 
intensity ratios of the two prominent Raman bands at 1447 cm
-1
 (CH2 mode proteins) 
and 785 cm
-1
 (ring breathing modes in DNA bases), I1447/I785, provided good 
diagnostic sensitivity (79%-87%) and specificity (81%-85%). The significant differences 
in the intensity ratios between the normal B-lymphocytes and the clinical patient B-ALL 
samples might reflect the relative changes in the concentrations of potential biological 
markers, as cell surface antigens, and cytoplasmic protein and DNA contents. 
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Additionally, despite the higher variability in the clinical patient B-ALL samples 
compared to the three B-leukemia cell lines, this Raman approach allowed significant 
discrimination between normal B-lymphocytes versus these B-ALL cells.  
This relatively simplistic empirical analysis only used a limited number of Raman peaks, 
and most of the information contained in the Raman spectra is not included. Therefore, I 
also performed PCA with these clinical samples. In more detail, the PCA algorithm 
achieved identification of each pathological clinical sample with a sensitivity from 88% 
to 94% and a specificity from 85% to 90%. These sensitivity and specificity data in this 
diagnosis provided by RS can now set the stage for more specific clinical studies. 
Further studies with both clinical samples before and after chemotherapy treatment will 
still be needed to understand the potential limitations of this RS approach.  
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7  
Classification of white 
blood cells 
In this chapter, I will show the feasibility of using RS and multivariate statistical 
approaches (PCA) to identify and discriminate leukocytes. We focused on five 
populations isolated from peripheral blood of several human volunteers via 
conventional flow cytometry: granulocytes (neutrophils), monocytes, T cells, B cells and 
NK cells. 
7.1 Introduction 
The direct identification of cells forms the basis of many analytical laboratory tests 
including those used in haematology and oncology diagnostics. One of the most 
important examples is the complete blood count (CBC), which is the most widely used 
clinical test ordered for almost every disease. 
Blood is an important body fluid, which contains three major corpuscular elements: red 
blood cells (or erythrocyte), white blood cells (or leukocytes) and platelets (or 
thrombocytes).  White blood cells (WBCs), also called leukocytes, are the cells of the 
immune system that are involved in protecting the body against infectious disease and 
foreign invaders. All white blood cells are nucleated, which distinguishes them from the 
anucleated red blood cells and platelets and can be divided into the three main types: 
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granulocytes, lymphocytes, and monocytes. These types are distinguished by their 
physical and functional characteristics. Monocytes and granulocytes belong to myeloid 
lineage whereas lymphocytes belong to lymphoid lineage. Granulocytes can be 
classified as neutrophils, eosinophils and basophils by their nucleus shape and by the 
presence of granules in the cytoplasm; lymphocytes include T cells, B cells, and natural 
killer (NK) cells. 
Most existing cell counting methods are based on optical detection techniques due to 
their minimal invasiveness, high registration speed, high spatial resolution, and ability to 
detect many physical parameters including scattering, polarization, absorption, and 
fluorescence. 
However, the most commonly used flow cytometers and automated cell counters are 
sizable, complex, and usually expensive. Moreover, such devices require the use of 
chemical reagents. The sample preparation process may be complicated and may need to 
be performed by professional medical personnel. 
In this work, I will show the capability of RS in the identification and classification of 
white blood cells. 
7.2 Raman identification of leukocytes  
I studied three different types of leukocytes (granulocytes, monocytes and lymphocytes) 
by Raman spectroscopy. I considered only the polymorphonuclear neutrophils as they 
form almost the 95% of the granulocyte population (basophils are <1% of the 
granulocyte population and eosinophils <5% of the granulocyte population). For the 
lymphocytes cells I preliminary considered only B and T cells as they form the major 
cellular components of the adaptive immune response. 
Table 7:  Main morphological characteristics of the leukocytes. 
Leucocytes Nuclear shape Cytoplasm Dimension (µm) 
Monocytes Lobulated/indented 
Occasionally vacuoles 
and granules 
15-30 
Lymphocytes 
(T and B cells) 
Large and regular Small amount 7-8 
Granulocytes 
(neutrophils) 
Multilobulated 
Presence of fine 
numerous granules 
10-15 
 
The three classes of studied leukocytes can be microscopically discriminate due to their 
specific shapes of nuclei, sizes and cellular components (Table 7).  Granulocytes have a 
diameter of about 10-15 µm, a multilobulated nucleus and cytoplasmic granules. 
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Monocytes are large cells 15-30 µm presenting a lobulated nucleus. Lymphocytes are 
the smaller leukocytes having a typical size of about 7-8 µm and single large nucleus. 
The three cell populations can be easily separated and identified by measuring the side 
(SSC) and forward (FSC) scatter of the cells by flow cytometry as shown in Figure 46. 
More precisely, the FSC provides a rough measure of the cells size, while the SSC is a 
measure of the complexity of the cell internal structures. The more “granular” a cell is 
the higher its SSC will be, as confirmed form the results of Figure 46. However, 
different flow cytometers will provide slightly different FCS and SSC measurements, 
depending on refractive index mismatches between sheath and sample, beam geometry 
and polarization, beam stop position and collecting angles.  Therefore, the specific 
labelling of the cell is required to improve the statistic. 
 
Figure 46: Differentiation of leukocytes by detection of the CD45-FSC and SSC parameters. 
In our experiments, leucocytes have been isolated from peripheral blood of healthy 
donors with informant consent according to the Ethics Committee of SDN (See Chapter 
3 for more details).  
The isolated cells were analysed for purity by flow cytometry. More precisely, CD45+ 
granulocytes were obtained at a purity level 95% (Figure 47); CD14+ monocytes were 
obtained at a purity level of 90% (Figure 48); CD3+, CD19+ lymphocytes were obtained 
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at a purity level of 95%. The fluorescence intensities were measured with a flow 
cytometer (FC-500; Beckman-Coulter, Milan, Italy), according to the manufacturer 
instructions. The percentage of granulocytes (CD45+, pan-leucocyte marker) was 
assessed before and after the Ficoll-Histopaque procedure. Instead, the percentages of 
lymphocytes and monocytes (CD14+/ CD56+; CD14+/ CD19+) were assessed after the 
immunomagnetic separation procedure.  
 
Figure 47: Dot plots for the determination of human granulocytes purification by flow 
cytometry. Percentage of granulocytes (CD45+) determined by flow cytometry before and after 
Ficoll procedure. 
 
Figure 48: Dot plots for the determination of human monocytes purification by flow 
cytometry. Percentage of monocytes (CD14+/CD56+; CD14+/CD19+) determined by flow 
cytometry, as pre-separation and post-separation through negative immunomagnetic selection. 
For the Raman measurements 1x10
6 
cells were suspended in 1ml of culture medium, a 
drop of the solution was placed on a quartz slide and the 15 spectra were acquired within 
15-20 min of removal from the culture medium. For each cell type, the cells analyzed 
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were derived from three different donors, to ensure that the observed differences were 
the result of biological variations rather than variations from donor to donor. 
To determine the RS markers that specifically identify differences in the biochemical 
compositions between the three types of leucocytes, a total of 100 Raman spectra from 
lymphocytes, monocytes and granulocytes have been acquired and analysed. The mean 
Raman spectra collected for each population are shown in Figure 49.  
 
Figure 49: Spectral identification of leucocytes. The mean Raman spectra of lymphocytes, 
monocytes and granulocytes are shown. Representative images of the cell morphology using 
May Grunwald-Giemsa histochemical staining for DNA and RNA molecules are additionally 
presented. 
 
Figure 50: Raman spectrum of isolated oxidized human myeloperoxidase. 
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At first glance, lymphocytes and monocytes Raman spectra show very similar spectral 
profile. As those spectra are acquired by focusing the laser probe on the cell nucleus 
nucleic acid contributions are clearly visible, such as ring breathing modes of the nucleic 
acid bases (730-750 cm
-1
 adenine, thymine ring breathing and at 1576 cm
-1
 guanine and 
adenine contributions) and from the O−P−O backbone (785 cm-1 and 1095 cm-1). 
However, due to large probed volume, the Raman system should also partially examine 
the membrane and cytoplasm above and below the nucleus. Indeed, typical vibrational 
contributions due to proteins such as the amide I band (around 1660 cm
-1
), the amide II 
band (around 1257 cm
-1
) and C-H bond (around 1445 cm
-1
) are clearly visible. The 
intense vibrational band around 1341 cm−1 has contributions from proteins and nucleic 
acids and to a minor extent also from carbohydrates. One of the major differences 
between monocytes and lymphocytes are the relative intensities of the nucleic acid and 
protein vibrational bands. This can be explained by a much larger nucleus in the 
lymphocytes, which almost fills the whole cell compared to a smaller indented nucleus 
in the monocytes.  
The granulocyte Raman spectrum presents some substantial spectral differences in the 
regions around 750-800 cm
-1
 and around 830, 980, 1350, 1540 cm
-1
 [129]. Indeed, 
strong signal contributions from myeloperoxidase (MPO), a peroxidase enzyme of the 
azurophilic granules, are present as is clear from the spectrum of the purified enzyme 
shown in Figure 50. Neutrophil granulocytes present a lot of cytoplasmic granules of 0.2 
µm in diameter (11), which contain a wide variety of oxidative metabolites and digestive 
enzymes, just as the MPO. MPO contains two covalently bound active site heme groups 
(47, 48) and therefore its contribution is resonantly enhanced at the excitation 
wavelength used in this work [134]. Their main functions are phagocytosis, killing, and 
digestion of bacteria and other microorganisms. 
7.3 Leukocyte statistical analysis 
To clarify the biochemical classification and spectral variations for monocytes, 
lymphocytes and granulocytes, I used an empirical analysis based on the intensity ratio 
of two prominent Raman bands, at 1447 cm
-1
 and 785 cm
-1
 (I1447/I785). Figure 51 shows 
the plot of the I1447/I785 ratios according to the cell types. The mean (± s.d.) of the ratio 
for the leucocytes  (Rleucocytes = 1.8 ± 0.3) was significantly different from the means of 
the monocytes (Rmonocytes= 5.2 ± 0.4) and granulocytes (Rgranulocytes= 8.2 ± 0.6). These 
differences reflected the relative changes in the potential biological markers from 
cytoplasmic proteins and DNA content. 
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Figure 51: Plot of the intensity ratios of the Raman signals at 1447 cm
−1
 and 785 cm
−1
 
(I1447/I785), for leukocytes, monocytes and granulocytes.  
The good classification results provided by the empirical analysis can be further 
increased with PCA analysis. Indeed, a very good separation of the three leukocyte 
subgroups can be achieved by considering the first three PCs. I selected the PC1, PC2 
and PC3 as they describe about 73%, 13% and 11% respectively of the total spectral 
variance. The relative score plot is presented in Figure 52 and clearly it reveals that the 
three cell populations formed distinct and well defined groups. Finally, the classification 
model was built with 300 spectra and cross-validated by leaving out each time one 
spectrum of the entire set. The results are shown in the confusion matrix of Table 8. Out 
of the totally 100 lymphocytes spectra, 95 spectra were assigned correctly, only 5 were 
misclassified and assigned to the monocytes. For the monocytes, 96 spectra have been 
assigned correctly and for the granulocytes 98 spectra have been assigned correctly. This 
yields an accuracy of 96.3%. 
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Figure 52: PCA scatter plot of lymphocytes, monocytes and granulocytes.  
Table 8: Confusion matrix for the classification of lymphocytes, monocytes and granulocytes. 
 Lymphocytes Monocytes Granulocytes 
Lymphocytes 95 5 0 
Monocytes 4 96 0 
Granulocytes 1 1 98 
7.4 Raman identification of lymphocytes   
This section describes a Raman spectroscopic investigation of human lymphocytes: T 
cells, B cells and natural killer (NK) cells. T cells (thymus cells) and B cells (bone 
marrow cells) are the cellular components of the adaptive immune response. T cells are 
involved in cell-mediated immunity, whereas B cells are involved in antibody-mediated 
immunity. NK cells are a part of the innate immune system and play an important role in 
destroying both cancer cells and virally infected cells. NK cells recognize infected cells 
and cancerous cells by changes of a surface molecule called MHC (major 
histocompatibility complex) class I [135].  
T cells, B cells and natural killer (NK) cells are very similar morphologically and can be 
identified by their large nucleus. It is impossible to distinguish microscopically between 
T cells, B cells and NK cells in a peripheral blood smear [136]. Routinely, the flow 
cytometry procedure is used to determine the percentage of lymphocytes that show 
specific cell surface proteins (immunoglobulins or CD markers) or that produce 
particular proteins (cytokines). 
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Figure 53: Dot plots for the determination of human lymphocyte purification by flow 
cytometry. Percentages of B cells (CD19+/CD3+; CD19+/CD56+), T cells (CD3+/CD56+; 
CD3+/CD19+) and natural killer cells (CD56+/CD3+; CD56+/CD19+) determined by flow 
cytometry, after the immunomagnetic separation procedure. 
The lymphocytes samples have been isolated from peripheral blood of three healthy 
donors (See Chapter 3 for more details). The isolated cells were analysed for purity by 
flow cytometry. In details, CD19+ B cells were obtained at a purity level of 90% (Figure 
53a); CD3+ T cells were obtained at a purity level of 95% (Figure 53b); CD56+ NK 
cells were obtained at a purity level of 90% (Figure 53c). The fluorescence intensities 
were measured with a flow cytometer (FC-500; Beckman-Coulter, Milan, Italy), 
 93 
according to the manufacturer instructions. The percentages of B-cells (CD19+/CD3+; 
CD19+/CD56+), T-cells (CD3+/CD56+; CD3+/CD19+) NK-cells (CD56+/CD3+; 
CD56+/CD19+) were assessed after the immunomagnetic separation procedure. 
 
Figure 54: Mean Raman spectra of B cells, T cells and NK cells.  
The mean Raman spectra on 100 acquisitions of B cells, T cells and NK cells are shown 
in Figure 54. The spectral profiles confirm that the analysed cell groups are 
morphological and biochemically very similar. The main differences between B and T 
cells can be seen in the spectral regions around 1150-1250 cm
-1
 (CN, CC, amide III band, 
proteins/lipids), 1310 cm
-1
 (amide III band), 1420-1485 cm
-1
 (CH proteins/lipids), 1607-
1617 (C=C vibrations) (Figure 54) [13][17][106][120][122]. In this case, the nucleic 
acid spectral regions are almost invariant. These spectral variations could be due to 
different expression of specific membrane proteins in B and T cells. The spectral 
variations it is especially visible by comparing the spectra of T and B cells with NK cells, 
confirming that NK cells are morphologically different from T and B cells. Indeed, NK 
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cells present small granules in their cytoplasm containing proteins such as perforin and 
proteases known as granzymes. 
7.5 Lymphocyte statistical evaluations  
Finally, I performed PCA to evaluate the discrimination efficiency between the three-
lymphocyte subpopulations, according to the RS. Figure 55 shows the PCA scatter plots 
of the PC1-3 concerning the 100 B cells, 100 T cells and 100 NK cells. The score plots 
clearly show well-separated and defined cell groups, confirming that our statistical 
approach allows efficiently identifying even slightly spectral differentiated cell groups.  
This graphical evaluation is confirmed by the data of the leave-one-out cross validation 
approach reported in the confusion matrix of Table 9. The mean diagonal values of the 
confusion matrix provide a total efficiency classification between the three-lymphocyte 
subpopulations of 94.6%.  
 
Figure 55: PCA scatter plots of B cells, T cells and NK cells. 
Table 9: Confusion matrix for the classification of B cells, T cells and NK cells. 
 B cells T cells NK cells 
B cells 91 7 2 
T cells 5 95 0 
NK cells 2 0 98 
7.6 Discussion and conclusions 
The ability to detect non-disruptively, in completely label-free manner distinct white 
blood cell subsets would be of significance in both in vivo and in vitro studies of the 
immune system. In this chapter, I used the Raman spectroscopy to successfully identify 
a number of important leucocytes subgroups (granulocytes, monocytes and 
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lymphocytes). One of the major spectral differences between monocytes and 
lymphocytes are the relative intensities of the nucleic acid and protein vibrational bands: 
750 and 785 cm
-1
 DNA bases, 1007 cm
-1
 symmetric ring breathing mode of 
phenylalanine, 1400-1500 cm
-1
 CH deformation proteins. This can be explained by a 
much larger nucleus in the lymphocytes, which almost fills the whole cell compared to a 
smaller indented nucleus in the monocytes. Even more differences were found in the 
Raman spectra of granulocytes, such as in the regions around 750-800 cm
-1
 and around 
830, 980, 1350, 1540 cm
-1
, due to the strong signal contribution from the 
myeloperoxidase (MPO), a peroxidase enzyme of the azurophilic granules [130]. Finally, 
a robust classification model could be built with PCA. This model was tested using the 
laving-one-out cross validation approach using leucocytes isolated in different days from 
the peripheral blood of three different healthy donors.  Only 11 leucocytes have been 
misclassified over the 300 analysed giving an overall accuracy of about 97%.   
The Raman spectroscopy and PCA combined approach has been additionally used to 
provide the biochemical signatures that could be used to specifically (up to 95%) 
identify T cells, B cells and NK cells.  
These are very promising results for future spectroscopic assignment of leucocytes 
subpopulations without the need of any staining solution.  
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Conclusion 
The research presented in this thesis was motivated by the need for label-free 
characterization methods of cells for diagnostic applications. This work described the 
development and application of a combination of single-cell Raman spectroscopy (RS) 
and principal component analysis (PCA) for investigation of leukocytes (hemogram) 
from peripheral blood of healthy donors as well as the identification and classification of 
cancer B-ALL cells.  
The developed Raman spectroscope has been preliminary validated by analysing three 
transformed B-leukemia cell lines (RS4;11, REH and MN60) cultured in vitro, which 
are useful model systems to study the pathophysiology of hematopoietic diseases. As 
these cell lines belong to the human B lymphoid lineage, their Raman spectra appear 
very similar. However, since RS4;11 and REH are L2 subtype, while MN60 is a L3 B-
ALL subtype, their spectra show subtle differences in the intensities of defined Raman 
peaks. In combination with immunofluorescence and Western blotting, I showed that 
these Raman markers reflect the relative changes in the potential biological markers 
from cell surface antigens, cytoplasmic proteins, and DNA content and correlate with 
the lymphoblastic B-cell maturation/differentiation stages. Additionally, the magnitude 
of the peak variations increased from the RS4;11 cells to the MN60 cells, in agreement 
with the extent of expression of plasma-membrane antigens, nucleus/cytoplasm ratio and 
cytoplasmic immunoglobulins during the B-cell differentiation/maturation process 
(Figure 30). Of note, the Raman spectrum of the MN60 B-leukemia cells was slightly 
different from those of both the RS4;11 and REH B-leukemia cells, which also 
confirmed that these MN60 B-leukemia cells can be classified as a distinct B-leukemia 
cell subtype, as indeed is the case based on its more differentiated maturation stage. 
Therefore, the distinctive differences in the Raman spectra between the normal B-
lymphocytes and the B-leukemia cells suggests that RS can be used to reveal molecular 
changes associated with these pathological transformations. I also explored PCA, 
together with a leave-one-out cross-validation approach, for B-leukemia cell 
identification and classification, which provided a diagnostic efficiency of 97.3% for 
separating B-leukemia versus normal B-lymphocytes. Notably, only two of 300 control 
cells were predicted incorrectly, and five of the B-leukemia cells were incorrectly 
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assigned to the normal B-lymphocyte group (Figure 32), and therefore the risk of false 
positives with this model appears to be minimal.  
The detection and classification of leukemia cells are only the first steps in the clinical 
management of leukemia patients. Constant cell monitoring of the chemotherapy effect 
could be crucial for improving treatment strategies and for the detection of minimal 
residual disease. For this purpose, I focused the present study on the maintenance 
therapies for patients with B-ALL, with the aim to suppress the drug-resistant population 
of B-leukemia cells. Using independent and complementary approaches, as 
immunofluorescence, Western blotting and RS, I identified some biological features that 
were modified under these B-ALL specific maintenance therapies (Figure 36, Figure 37, 
Figure 38). Of note, low-dose treatments were used here to better analyze the accuracy 
of our approaches for the detection of these specific biochemical changes. In more detail, 
under both MTX and 6MP treatments, all three of these B-leukemia cell lines showed B-
leukemia regression through the reversing of the B-cell differentiation/maturation 
process, which was identified and classified according to the specific antigen expression 
profiles, and promoted changes in the nucleic acid contents without any apoptotic effects. 
These specific modifications should be explained by the mechanisms of action of the 
chemotherapeutic drugs used in this study. Interestingly, both MTX and 6MP treatments 
similarly affected the Raman spectra of these three B-leukemia cells, with reduced 
intensities of peaks related to DNA, RNA and protein content. To demonstrate the 
specific ability of this RS approach for the detection of the anti-leukemic effects of 
MTX and 6MP treatments on these B-leukemia cells we used ATRA treatment as a 
control. The Raman spectra of the ATRA-treated and nontreated B-leukemia cells did 
not show any significant differences. 
Additionally, the PCA scatter plots and the cross-validation data demonstrated that 
although the MTX-treated (or 6MP-treated) B-leukemia cells showed reduced 
expression of plasma membrane antigens and DNA, their spectra could be separated 
from the normal B-lymphocytes with an efficiency of about 99%. These findings 
confirmed that specific Raman markers could be used to discriminate normal from both 
leukemia cells and leukemia cells under maintenance treatment and suggested that RS 
could be used in the detection of minimal residual disease. 
I additionally extended the Raman approach to three clinical patient samples. Two 
patients had the preliminary classification of ‘common B-ALL’, the third patient was 
preliminary classified in between the pro-B and pre-B maturation stages. The distinctive 
differences in the Raman spectra between the normal and the clinical samples confirmed 
and further reinforced these observations. I also performed PCA with these clinical 
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samples. From this PCA analysis, several considerations arose: (i) the spectral 
variability in these clinical samples was more pronounced compared to the B-leukemia 
cell lines; (ii) the REH B-leukemia cell data fell within a smaller region defined by the 
B-ALL cells from Pt-1 and Pt-2; (iii) the data for the B-ALL cells from Pt-3 showed 
better demarcation from normal B-lymphocytes, and thus these B-ALL cells from Pt-3 
were more differentiated than those from Pt-1 and Pt-2, and showed an intermediate 
behavior to that of the REH and MN60 B-leukemia cell lines; and (iv) RS can be used to 
differentiate between normal B-lymphocytes and clinical samples from patients with B-
ALL with high sensitivity and specificity. In more detail, the PCA algorithm achieved 
identification of each pathological clinical sample with a sensitivity from 88% to 94% 
and a specificity from 85% to 90%. These sensitivity and specificity data in this 
diagnosis provided by RS can now set the stage for more specific clinical studies.  
Finally, I showed that RS has been able to identify and distinguish leukocytes. In this 
proof-of-principle study, I focused on the most important white blood cells populations 
isolated from peripheral blood of several human volunteers via conventional flow 
cytometry: granulocytes (neutrophils), monocytes and lymphocytes (T cells, B cells and 
NK cells). I demonstrated the capability of Raman spectroscopy in the identification and 
classification of leukocytes and, more in details, of the three lymphocytes groups (Figure 
49, Figure 54). With the aid of statistical models, it was possible to discriminate between 
cell types based on the specific information present in the Raman spectra. The high 
identification accuracy (about 97%) indicates that the heterogeneity due to person-to-
person variability and sample preparations on different days has minimum influence.  
In conclusion, this study shows that RS and PCA allow differentiation between normal 
B-lymphocytes and B-ALL cells at different maturation stages, which has important 
implications for clinical practice. The feature-rich and specific Raman spectra offers the 
possibility of highly multi-parameter measurements that could represent a major step 
forward towards the realization of a non-destructive, label-free Raman-based flow 
cytometer for blood cell identification. Further studies with both clinical samples before 
and after chemotherapy treatment will still be needed to understand the potential 
limitations of this RS approach. 
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ABSTRACT 
X- and Y-chromosome-bearing sperm cell sorting is of great interest, especially for 
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demonstrate an optical method based on Raman spectroscopy to separate X- and Y-
chromosome-bearing sperm cells, overcoming many of the limitations associated with 
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ABSTRACT 
A full label-free morphological and biochemical characterization is desirable to select 
spermatozoa during preparation for artificial insemination. In order to study these 
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holography (DH) and Raman spectroscopy (RS). DH presents new opportunities for 
studying morphological aspect of cells and tissues non-invasively, quantitatively and 
without the need for staining or tagging, while RS is a very specific technique allowing 
the biochemical analysis of cellular components with a spatial resolution in the sub-
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RS study was performed to identify X- and Y-chromosome-bearing sperm cells. We 
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phases inclusions (precipitates) and providing an instrument to discriminate among 
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